Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
28 "Child"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Pediatric cancer
Long-term Outcomes of Protocol-Based Treatment for Newly Diagnosed Medulloblastoma
Won Kee Ahn, Seung Min Hahn, Hong In Yoon, Jeongshim Lee, Eun Kyung Park, Kyu Won Shim, Dong Seok Kim, Chang-Ok Suh, Se Hoon Kim, Chuhl Joo Lyu, Jung Woo Han
Cancer Res Treat. 2024;56(2):652-664.   Published online November 30, 2023
DOI: https://doi.org/10.4143/crt.2023.865
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The Korean Society of Pediatric Neuro-Oncology (KSPNO) conducted treatment strategies for children with medulloblastoma (MB) by using alkylating agents for maintenance chemotherapy or tandem high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCR) according to the risk stratification. The purpose of the study was to assess treatment outcomes and complications based on risk-adapted treatment and HDC.
Materials and Methods
Fifty-nine patients diagnosed with MB were enrolled in this study. Patients in the standard-risk (SR) group received radiotherapy (RT) after surgery and chemotherapy using the KSPNO M051 regimen. Patients in the high-risk (HR) group received two and four chemotherapy cycles according to the KSPNO S081 protocol before and after reduced RT for age following surgery and two cycles of tandem HDC with ASCR consolidation treatment.
Results
In the SR group, 24 patients showed 5-year event-free survival (EFS) and overall survival (OS) estimates of 86.7% (95% confidence interval [CI], 73.6 to 100) and 95.8% (95% CI, 88.2 to 100), respectively. In the HR group, more infectious complications and mortality occurred during the second HDC than during the first. In the HR group, the 5-year EFS and OS estimates were 65.5% (95% CI, 51.4 to 83.4) and 72.3% (95% CI, 58.4 to 89.6), respectively.
Conclusion
High intensity of alkylating agents for SR resulted in similar outcomes but with a high incidence of hematologic toxicity. Tandem HDC with ASCR for HR induced favorable EFS and OS estimates compared to those reported previously. However, infectious complications and treatment-related mortalities suggest that a reduced chemotherapy dose is necessary, especially for the second HDC.

Citations

Citations to this article as recorded by  
  • Ferroptosis Transcriptional Regulation and Prognostic Impact in Medulloblastoma Subtypes Revealed by RNA-Seq
    Christophe Desterke, Yuanji Fu, Jenny Bonifacio-Mundaca, Claudia Monge, Pascal Pineau, Jorge Mata-Garrido, Raquel Francés
    Antioxidants.2025; 14(1): 96.     CrossRef
  • 3,142 View
  • 154 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Hematologic malignancy
Clinical Impact of Drug Adherence of Tyrosine Kinase Inhibitors in Children with Ph-Positive Acute Lymphoblastic Leukemia
Jun-Xia Wang, Miao-Miao Yang, Li-Peng Liu, Hui-Min Zhang, Meng-Chuan Wang, Yu-Wen Chen, Xiao-Ying Zang, Fang Hu
Cancer Res Treat. 2023;55(3):1023-1030.   Published online February 6, 2023
DOI: https://doi.org/10.4143/crt.2022.1618
AbstractAbstract PDFPubReaderePub
Purpose
This study aimed to explore the impact of ABL1–tyrosine kinase inhibitors (TKIs) adherence on the survival of chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) children and clarify the potential predictors of patients’ prognosis from TKIs intake practices.
Materials and Methods
Ninety newly diagnosed Ph+ ALL patients who received TKIs were enrolled. We collected the baseline characteristics and adverse events in all children; moreover, TKIs adherence was measured by an eight-item Morisky medication adherence scale (MMAS-8). Progression-free survival (PFS) and overall survival (OS) analysis were performed, and risk factors for PFS and OS were evaluated.
Results
Among all patients, 69 cases were regarded as adherers, while 21 were non-adherers. The median duration of TKIs interruption was significantly prolonged in the non-adherence group than in the adherence group (13 [0-101] vs. 56 [11-128], p < 0.001). Additionally, dose reduction occurred in 55.2% of non-adherers versus 23.0% of adherers (p=0.002). The PFS and OS in adherers were significantly higher versus non-adherers (p=0.020 and p=0.039). MMAS-8 score was an independent risk factor for PFS (p=0.010) and OS (p=0.031). Among non-adherers, the median OS was only 23.1% (4.2%-42%) in patients aged ≤ 10 years versus 54.4% (38.8%-70%) in adolescents. Most of the patients who experienced TKIs non-adherence suffered pancytopenia.
Conclusion
TKIs adherence during treatment significantly influenced the survival of pediatric Ph+ ALL patients, and non-adherers with age ≤ 10 years were more vulnerable to TKIs disruption. The cumulative TKIs dose should be especially emphasized to patients with age ≤ 10 years, which may result in an inferior achievement of relevant treatment milestones.
  • 2,976 View
  • 143 Download
Close layer
Pediatric cancer
Gonadal Function in Female Adolescent and Young Adult Survivors of Childhood Cancer
Hye Young Jin, Jun Ah Lee, Meerim Park, Hyeon Jin Park
Cancer Res Treat. 2023;55(3):992-1000.   Published online January 31, 2023
DOI: https://doi.org/10.4143/crt.2022.1518
AbstractAbstract PDFPubReaderePub
Purpose
Childhood cancer survivors (CCSs) are at risk for premature ovarian insufficiency (POI). The aim of this study is to evaluate ovarian function and associated health outcomes in female adolescent and young adult survivors of childhood cancer.
Materials and Methods
Sixty-nine female CCSs were enrolled. Medical records of CCSs were retrospectively reviewed. The subjects were categorized into three groups according to follicular stimulating hormone (FSH) levels (cutoff, 12, 40 IU/L). Anti-müllerian hormone (AMH) level less than 1 ng/mL was considered low AMH level.
Results
Of 69 subjects, 14 (20.3%) had POI and 14 (20.3%) had FSH levels between 12 and 40 IU/L. Forty-one of 69 (59.4%) had normal FSH levels. Pelvic irradiation and stem cell transplantation (SCT) were more frequently performed in subjects with POI (p=0.001 and p < 0.001). AMH levels were remarkably low when FSH levels were over 12 IU/L (p < 0.001). In multivariate analysis, cyclophosphamide equivalent dose and SCT were significant treatment factors for developing low AMH levels (p=0.005 and p=0.002, respectively). Total, low-density lipoprotein cholesterol and triglyceride were significantly different in three groups according to FSH levels (p=0.047, p=0.030, and p=0.045). Z-score of femur neck bone mineral density was significantly reduced when FSH levels were increased (p=0.011).
Conclusion
Gonadal dysfunction is common in CCSs. Gonadal function was associated with a few treatment factors known to increase the risk of POI. Regular monitoring of gonadal function is needed for better health outcomes.

Citations

Citations to this article as recorded by  
  • Systematic Review of the Gonadotoxicity and Risk of Infertility of Soft Tissue Sarcoma Chemotherapies in Pre- and Postpubertal Females and Males
    Marcel Steinmann, Anita Rietschin, Flavia Pagano, Tanya Karrer, Attila Kollár, Susanna Weidlinger, Michael von Wolff
    Journal of Adolescent and Young Adult Oncology.2024; 13(6): 803.     CrossRef
  • Bone Mineral Density in Survivors of Childhood Cancer: A Meta-Analysis
    Lilly Velentza, Panagiotis Filis, Mari Wilhelmsson, Per Kogner, Nikolas Herold, Lars Sävendahl
    Pediatrics.2024;[Epub]     CrossRef
  • 3,351 View
  • 166 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Epidemiologic and Clinical Outcomes of Pediatric Renal Tumors in Korea: A Retrospective Analysis of The Korean Pediatric Hematology and Oncology Group (KPHOG) Data
Kyung-Nam Koh, Jung Woo Han, Hyoung Soo Choi, Hyoung Jin Kang, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Kyung Taek Hong, Jung Yoon Choi, Sung Han Kang, Hyery Kim, Ho Joon Im, Seung Min Hahn, Chuhl Joo Lyu, Hee-Jo Baek, Hoon Kook, Kyung Mi Park, Eu Jeen Yang, Young Tak Lim, Seongkoo Kim, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Meerim Park, Hyeon Jin Park, Byung-Kiu Park, Jun Ah Lee, Jun Eun Park, Soon Ki Kim, Ji Yoon Kim, Hyo Sun Kim, Youngeun Ma, Kyung Duk Park, Sang Kyu Park, Eun Sil Park, Ye Jee Shim, Eun Sun Yoo, Kyung Ha Ryu, Jae Won Yoo, Yeon Jung Lim, Hoi Soo Yoon, Mee Jeong Lee, Jae Min Lee, In-Sang Jeon, Hye Lim Jung, Hee Won Chueh, Seunghyun Won, the Korean Pediatric Hematology and Oncology Group (KPHOG)
Cancer Res Treat. 2023;55(1):279-290.   Published online August 11, 2022
DOI: https://doi.org/10.4143/crt.2022.073
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Renal tumors account for approximately 7% of all childhood cancers. These include Wilms tumor (WT), clear cell sarcoma of the kidney (CCSK), malignant rhabdoid tumor of the kidney (MRTK), renal cell carcinoma (RCC), congenital mesoblastic nephroma (CMN) and other rare tumors. We investigated the epidemiology of pediatric renal tumors in Korea.
Materials and Methods
From January 2001 to December 2015, data of pediatric patients (0–18 years) newly-diagnosed with renal tumors at 26 hospitals were retrospectively analyzed.
Results
Among 439 patients (male, 240), the most common tumor was WT (n=342, 77.9%), followed by RCC (n=36, 8.2%), CCSK (n=24, 5.5%), MRTK (n=16, 3.6%), CMN (n=12, 2.7%), and others (n=9, 2.1%). Median age at diagnosis was 27.1 months (range 0-225.5) and median follow-up duration was 88.5 months (range 0-211.6). Overall, 32 patients died, of whom 17, 11, 1, and 3 died of relapse, progressive disease, second malignant neoplasm, and treatment-related mortality. Five-year overall survival and event free survival were 97.2% and 84.8% in WT, 90.6% and 82.1% in RCC, 81.1% and 63.6% in CCSK, 60.3% and 56.2% in MRTK, and 100% and 91.7% in CMN, respectively (p < 0.001).
Conclusion
The pediatric renal tumor types in Korea are similar to those previously reported in other countries. WT accounted for a large proportion and survival was excellent. Non-Wilms renal tumors included a variety of tumors and showed inferior outcome, especially MRTK. Further efforts are necessary to optimize the treatment and analyze the genetic characteristics of pediatric renal tumors in Korea.

Citations

Citations to this article as recorded by  
  • Congenital Mesoblastic Nephroma Mimic Wilms Tumor on 18F-FDG PET/CT and PET/MR
    Wenzhu Hu, Chunxia Qin, Fuqiang Shao, Mengting Li, Xiaoli Lan
    Clinical Nuclear Medicine.2024; 49(4): 353.     CrossRef
  • Progress towards Therapies for Solid Renal Tumors in Children
    洁 林
    Advances in Clinical Medicine.2024; 14(06): 245.     CrossRef
  • 7,066 View
  • 190 Download
  • 1 Web of Science
  • 2 Crossref
Close layer
Outcome of Intensive Therapy for Children with Relapsed Acute Myeloid Leukemia: A Single Institution Korean Study
Jae Wook Lee, Jae Won Yoo, Seongkoo Kim, Pil-Sang Jang, Nack-Gyun Chung, Bin Cho
Cancer Res Treat. 2022;54(4):1230-1239.   Published online December 17, 2021
DOI: https://doi.org/10.4143/crt.2021.1011
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Approximately 30%-40% of pediatric acute myeloid leukemia (AML) patients relapse. In this study, we analyzed the outcome and prognostic factors of relapsed AML patients who had previously received first-line therapy at our institution.
Materials and Methods
The study group consisted of 50 patients who had been diagnosed with AML from April 2009 to December 2018, and then showed first relapse. Thirty-two of the patients (64%) had previously received allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission (CR).
Results
Forty-five of the patients (90%) received intensive chemotherapy upon diagnosis of relapse, and 76% (34/45) of these patients achieved a second CR. Estimated 5-year overall survival for these 45 patients was 44.9%±7.6%. Time from diagnosis to relapse, extramedullary involvement (EMI) at diagnosis, core binding factor AML, and complex karyotype were significant prognostic factors; in multivariate study, both time from diagnosis to relapse and EMI at diagnosis proved significant. There was no difference in 5-year disease-free survival between patients previously treated with chemotherapy only and those who received HSCT in first CR (52.4%±14.9% vs. 52.6%±11.5%). Of the 19 patients who achieved second CR after previous allogeneic HSCT in first CR and subsequent relapse, 11 were treated with chemotherapy only, and seven survive disease-free.
Conclusion
Intensive therapy allowed for long-term survival in 40%-50% of patients, and 50% of patients who achieved second CR, regardless of prior treatment modalities in first CR. Intensive treatment may allow for salvage of a significant portion of patients with relapsed pediatric AML.

Citations

Citations to this article as recorded by  
  • Diagnosis and Treatment of Pediatric Acute Megakaryoblastic Leukemia with NUP98::KDM5A Rearrangement: Case Report
    Hyemin Kang, Suejung Jo, Jae Won Yoo, Seongkoo Kim, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Chae Yeon Lee, Myungshin Kim
    Clinical Pediatric Hematology-Oncology.2024; 31(2): 56.     CrossRef
  • 5,353 View
  • 115 Download
  • 1 Crossref
Close layer
Epidemiology of Acute Leukemia among Children with Down Syndrome in Korea
Young Bae Choi, Keon Hee Yoo
Cancer Res Treat. 2022;54(2):572-578.   Published online August 10, 2021
DOI: https://doi.org/10.4143/crt.2021.368
AbstractAbstract PDFPubReaderePub
Purpose
Children with Down syndrome (DS) show a higher risk of acute leukemia than those without DS. In this study, we investigated the nationwide incidence of acute leukemia among children with DS and compared their epidemiologic characteristics with those of children with acute leukemia but without DS.
Materials and Methods
Using the National Health Insurance Service database, we selected patients with acute leukemia aged 0–19 years at diagnosis between 2007 and 2016.
Results
Among the 4,697 children with acute leukemia, 54 (1.1%) had DS. The median incidence rate of leukemia with DS by year was 1.3% (range, 0.2%–2.0%). Sixteen patients with acute lymphoblastic leukemia (ALL; 29.6%) and 36 with acute myeloid leukemia (AML; 66.7%) had DS. The DS group showed younger age at diagnosis than the non-DS group, and diagnosis of AML was more frequent in the DS group than in the non-DS group (3 years vs. 9 years, p<0.001; 66.7% vs. 32.4%, P<0.001, respectively). The 5-year overall survival was comparable between the DS and non-DS groups (88.0% vs. 81.9%, p=0.375). Among all the Koreans born between 2007 and 2008, the incidences of acute leukemia, ALL, and AML were 49.25, 20.75, and 163.38 times higher, respectively, in the DS group than in the non-DS group.
Conclusion
Our findings support the fact that the incidence of acute leukemia is higher among patients with DS than among those without DS in Korea. However, the DS and non-DS groups in this study had a comparable overall survival rate.

Citations

Citations to this article as recorded by  
  • Cancer risks related to intellectual disabilities: A systematic review
    Amina Banda, Jenneken Naaldenberg, Aura Timen, Agnies van Eeghen, Geraline Leusink, Maarten Cuypers
    Cancer Medicine.2024;[Epub]     CrossRef
  • 5,634 View
  • 130 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group
Kyung Mi Park, Keon Hee Yoo, Seong Koo Kim, Jae Wook Lee, Nack-Gyun Chung, Hee Young Ju, Hong Hoe Koo, Chuhl Joo Lyu, Seung Min Han, Jung Woo Han, Jung Yoon Choi, Kyung Taek Hong, Hyoung Jin Kang, Hee Young Shin, Ho Joon Im, Kyung-Nam Koh, Hyery Kim, Hoon Kook, Hee Jo Baek, Bo Ram Kim, Eu Jeen Yang, Jae Young Lim, Eun Sil Park, Eun Jin Choi, Sang Kyu Park, Jae Min Lee, Ye Jee Shim, Ji Yoon Kim, Ji Kyoung Park, Seom Gim Kong, Young Bae Choi, Bin Cho, Young Tak Lim
Cancer Res Treat. 2022;54(1):269-276.   Published online April 20, 2021
DOI: https://doi.org/10.4143/crt.2021.313
AbstractAbstract PDFPubReaderePub
Purpose
Acute promyelocytic leukemia (APL) is a rare disease in children and there are some different characteristics between children and adult. We aimed to evaluate incidence, clinical characteristics and treatment outcomes of pediatric APL in Korea.
Materials and Methods
Seventy-nine pediatric APL patients diagnosed from January 2009 to December 2016 in 16 tertiary medical centers in Korea were reviewed retrospectively.
Results
Of 801 acute myeloid leukemia children, 79 (9.9%) were diagnosed with APL. The median age at diagnosis was 10.6 years (range, 1.3 to 18.0). Male and female ratio was 1:0.93. Thirty patients (38.0%) had white blood cell (WBC) count greater than 10×109/L at diagnosis. All patients received induction therapy consisting of all-trans retinoic acid and chemotherapy. Five patients (6.6%) died during induction chemotherapy and 66 patients (86.8%) achieved complete remission (CR) after induction chemotherapy. The causes of death were three intracranial hemorrhage, one cerebral infarction, and one sepsis. Five patients (7.1%) suffered a relapse during or after maintenance chemotherapy. The estimated 4-year event-free survival and overall survival (OS) rates were 82.1%±4.4%, 89.7%±5.1%, respectively. The 4-year OS was significantly higher in patients with initial WBC < 10×109/L than in those with initial WBC ≥ 10×109/L (p=0.020).
Conclusion
This study showed that the CR rates and survival outcomes in Korean pediatric APL patients were relatively good. The initial WBC count was the most important prognostic factor and most causes of death were related to serious bleeding in the early stage of treatment.

Citations

Citations to this article as recorded by  
  • Management of Acute Promyelocytic Leukemia at Extremes of Age
    Sabine Kayser, Shannon E. Conneely
    Cancers.2023; 15(14): 3637.     CrossRef
  • Current Challenges of Asian National Children's Cancer Study Groups on Behalf of Asian Pediatric Hematology and Oncology Group
    Chi-kong Li, Purna Kurkure, Ramandeep Singh Arora, Bow Wen Chen, Kirill Kirgizov, Yasuhiro Okamoto, Panya Seksarn, Yongmin Tang, Keon Hee Yoo, Bharat Agarwal, Godfrey C.F. Chan, Rashmi Dalvi, Hiroki Hori, Muhammad Saghir Khan, Alice Yu, Akira Nakagawara
    JCO Global Oncology.2023;[Epub]     CrossRef
  • Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad, Iraq. Improved results with ATRA extended consolidation
    Anna Maria Testi, Mazin Faisal Al-Jadiry, Hasanein Habeeb Ghali, Samaher Abdulrazzaq Fadhil, Amir Fadhil Al-Darraji, Raghad Majid Al-Saeed, Ahmed Hatem Sabhan, Safaa A. Faraj Al-Badri, Wisan Majeed Abed, Najiha Ahmed Ameen, Ruaa Zaki Al-Tameemi, Arabiya I
    Leukemia & Lymphoma.2022; 63(12): 2940.     CrossRef
  • Death due to unsuspected acute myeloid leukaemia: an unusual forensic diagnosis
    Lila Krebs-Drouot, Georgia Karpathiou, Virginie Scolan, Carolyne Bidat-Callet, Baptiste Boyer, Michel Péoc’h
    Forensic Science, Medicine and Pathology.2022; 19(1): 60.     CrossRef
  • Successful Treatment of Isolated Central Nervous System Relapse with Intrathecal Chemotherapy in an Adolescent with Acute Promyelocytic Leukemia
    Haerim Song, Eun Sang Yi
    Clinical Pediatric Hematology-Oncology.2022; 29(2): 70.     CrossRef
  • 7,781 View
  • 228 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Children’s Hepatic Tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS) System for Pediatric Patients with Hepatoblastoma: A Retrospective, Hospital-Based Cohort Study in South Korea
Pyeong Hwa Kim, Hyun Joo Shin, Hee Mang Yoon, Young Hun Choi, Jung-Man Namgoong, Dae Yeon Kim, Kyung-Nam Koh, Mi-Jung Lee, Haesung Yoon, Chuhl Joo Lyu, Jung Woo Han, Seung Min Hahn, Young Ah Cho
Cancer Res Treat. 2022;54(1):253-258.   Published online March 24, 2021
DOI: https://doi.org/10.4143/crt.2021.265
AbstractAbstract PDFPubReaderePub
Purpose
In 2017, the Children’s Hepatic Tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS) system was introduced. We aimed to evaluate the accuracy of CHIC-HS System for the prediction of event-free survival (EFS) in Korean pediatric patients with hepatoblastoma.
Materials and Methods
This two-center retrospective study included consecutive Korean pediatric patients with histopathologically confirmed hepatoblastoma from March 1988 through September 2019. We compared EFS among four risk groups according to the CHIC-HS system. Discriminatory ability of CHIC-HS system was also evaluated using optimism-corrected C-statistics. Factors associated with EFS were explored using multivariable Cox regression analysis.
Results
We included 129 patients (mean age, 2.6±3.3 years; female:male, 63:66). The 5-year EFS rates in the very low, low, intermediate, and high-risk groups, according to the CHIC-HS system were 90.0%, 82.8%, 73.5%, and 51.3%, respectively. The CHIC-HS system aligned significantly well with EFS outcomes (p=0.004). The optimism-corrected C index of CHIC-HS was 0.644 (95% confidence interval [CI], 0.561 to 0.727). Age ≥ 8 (vs. age ≤ 2; hazard ratio [HR], 2.781; 95% CI, 1.187 to 6.512; p=0.018), PRE-Treatment EXTent of tumor (PRETEXT) stage IV (vs. PRETEXT I or II; HR, 2.774; 95% CI, 1.228 to 5.974; p=0.009), and presence of metastasis (HR, 2.886; 95% CI, 1.457 to 5.719; p=0.002), which are incorporated as the first three nodes in the CHIC-HS system, were independently associated with EFS.
Conclusion
The CHIC-HS system aligned significantly well with EFS outcomes in Korean pediatric patients with hepatoblastoma. Age group, PRETEXT stage, and presence of metastasis were independently associated with EFS.

Citations

Citations to this article as recorded by  
  • Elevated serum uric acid is associated with the risk of advanced staging and vascular involvement in patients with hepatoblastoma: a 14-year retrospective study
    Yunlan Zhou, Jinning Li, Yanhui Ma, Mengjie Tang, Xiaojun Yuan, Lisong Shen
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • 6,234 View
  • 211 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Central nervous system
Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System in Children under the Age of 3 Years
Meerim Park, Jung Woo Han, Seung Min Hahn, Jun Ah Lee, Joo-Young Kim, Sang Hoon Shin, Dong-Seok Kim, Hong In Yoon, Kyung Taek Hong, Jung Yoon Choi, Hyoung Jin Kang, Hee Young Shin, Ji Hoon Phi, Seung-Ki Kim, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Do Hoon Lim, Hyung Jin Shin, Hyery Kim, Kyung-Nam Koh, Ho Joon Im, Seung Do Ahn, Young-Shin Ra, Hee-Jo Baek, Hoon Kook, Tae-Young Jung, Hyoung Soo Choi, Chae-Yong Kim, Hyeon Jin Park, Chuhl Joo Lyu
Cancer Res Treat. 2021;53(2):378-388.   Published online October 28, 2020
DOI: https://doi.org/10.4143/crt.2020.756
AbstractAbstract PDFPubReaderePub
Purpose
Atypical teratoid/rhabdoid tumor (ATRT) is a highly aggressive malignancy with peak incidence in children aged less than 3 years. Standard treatment for central nervous system ATRT in children under the age of 3 years have not been established yet. The objective of this study was to analyze characteristics and clinical outcomes of ATRT in children aged less than 3 years.
Materials and Methods
A search of medical records from seven centers was performed between January 2005 and December 2016.
Results
Forty-three patients were enrolled. With a median follow-up of 90 months, 27 patients (64.3%) showed at least one episode of disease progression (PD). The first date of PD was at 160 days after diagnosis. The 1- and 3-year progression-free survivals (PFS) were 51.2% and 28.5%, respectively. The 1- and 3-year overall survivals were 61.9% and 38.1%, respectively. The 3-year PFS was improved from 0% in pre-2011 to 47.4% in post-2011. Excluding one patient who did not receive any further therapy after surgery, 27 patients died due to PD (n=21), treatment-related toxicity (n=5), or unknown cause (n=1). In univariate analysis, factors associated with higher 3-year PFS were no metastases, diagnosis after 2011, early adjuvant radiotherapy, and high-dose chemotherapy (HDCT). In multivariate analysis, the use of HDCT and adjuvant radiotherapy remained significant prognostic factors for PFS (both p < 0.01).
Conclusion
Aggressive therapy including early adjuvant radiotherapy and HDCT could be considered to improve outcomes of ATRT in children under the age of 3 years.

Citations

Citations to this article as recorded by  
  • Metabolic profiling of patient-derived organoids reveals nucleotide synthesis as a metabolic vulnerability in malignant rhabdoid tumors
    Marjolein M.G. Kes, Francisco Morales-Rodriguez, Esther A. Zaal, Terezinha de Souza, Natalie Proost, Marieke van de Ven, Marry M. van den Heuvel-Eibrink, Jeroen W.A. Jansen, Celia R. Berkers, Jarno Drost
    Cell Reports Medicine.2025; 6(1): 101878.     CrossRef
  • Supratentorial ATRT in a young Infant: Expanding the diagnostic spectrum beyond medulloblastoma
    Ali Msheik, Mohamad Aoun, Youssef Fares
    Interdisciplinary Neurosurgery.2024; 35: 101857.     CrossRef
  • Radiation Therapy Plays an Important Role in the Treatment of Atypical Teratoid/Rhabdoid Tumors: Analysis of the EU-RHAB Cohorts and Their Precursors
    Sabine Frisch, Hanna Libuschewski, Sarah Peters, Joachim Gerß, Katja von Hoff, Rolf-Dieter Kortmann, Karolina Nemes, Stefan Rutkowski, Martin Hasselblatt, Torsten Pietsch, Michael C. Frühwald, Beate Timmermann
    International Journal of Radiation Oncology*Biology*Physics.2024; 119(4): 1147.     CrossRef
  • An adult with recurrent atypical teratoid rhabdoid tumor of the spine
    Antoinette J Charles, Vanessa L Smith, C Rory Goodwin, Margaret O Johnson
    CNS Oncology.2024;[Epub]     CrossRef
  • Dynamic Survival Risk Prognostic Model and Genomic Landscape for Atypical Teratoid/Rhabdoid Tumors: A Population-Based, Real-World Study
    Sihao Chen, Yi He, Jiao Liu, Ruixin Wu, Menglei Wang, Aishun Jin
    Cancers.2024; 16(5): 1059.     CrossRef
  • ESTRO-SIOPE guideline: Clinical management of radiotherapy in atypical teratoid/rhabdoid tumors (AT/RTs)
    Beate Timmermann, Claire Alapetite, Karin Dieckmann, Rolf-Dieter Kortmann, Yasmin Lassen-Ramshad, John H. Maduro, Monica Ramos Albiac, Umberto Ricardi, Damien C. Weber
    Radiotherapy and Oncology.2024; 196: 110227.     CrossRef
  • Development and epigenetic regulation of Atypical teratoid/rhabdoid tumors in the context of cell-of-origin and halted cell differentiation
    Laura Huhtala, Goktug Karabiyik, Kirsi J Rautajoki
    Neuro-Oncology Advances.2024;[Epub]     CrossRef
  • Comparative treatment results of children with atypical teratoid/rhabdoid tumor of the central nervous system in the younger age group
    L. V. Olkhova, O. G. Zheludkova, L. S. Zubarovskaya, A. S. Levashov, A. Yu. Smirnova, Yu. V. Dinikina, Yu. V. Kushel, A. G. Melikyan, S. K. Gorelyshev, M. V. Ryzhova, Yu. Yu. Trunin, A. G. Gevorgyan, O. B. Polushkina, V. E. Popov, L. P. Privalova, N. B. Y
    Russian Journal of Pediatric Hematology and Oncology.2023; 10(1): 11.     CrossRef
  • Current Challenges of Asian National Children's Cancer Study Groups on Behalf of Asian Pediatric Hematology and Oncology Group
    Chi-kong Li, Purna Kurkure, Ramandeep Singh Arora, Bow Wen Chen, Kirill Kirgizov, Yasuhiro Okamoto, Panya Seksarn, Yongmin Tang, Keon Hee Yoo, Bharat Agarwal, Godfrey C.F. Chan, Rashmi Dalvi, Hiroki Hori, Muhammad Saghir Khan, Alice Yu, Akira Nakagawara
    JCO Global Oncology.2023;[Epub]     CrossRef
  • Survival and Malignant Transformation of Pineal Parenchymal Tumors: A 30-Year Retrospective Analysis in a Single-Institution
    Tae-Hwan Park, Seung-Ki Kim, Ji Hoon Phi, Chul-Kee Park, Yong Hwy Kim, Sun Ha Paek, Chang-Hyun Lee, Sung-Hye Park, Eun Jung Koh
    Brain Tumor Research and Treatment.2023; 11(4): 254.     CrossRef
  • Atypical Teratoid/Rhabdoid Tumor in Taiwan: A Nationwide, Population-Based Study
    Yen-Lin Liu, Min-Lan Tsai, Chang-I Chen, Noi Yar, Ching-Wen Tsai, Hsin-Lun Lee, Chia-Chun Kuo, Wan-Ling Ho, Kevin Li-Chun Hsieh, Sung-Hui Tseng, James S. Miser, Chia-Yau Chang, Hsi Chang, Wen-Chang Huang, Tai-Tong Wong, Alexander T. H. Wu, Yu-Chun Yen
    Cancers.2022; 14(3): 668.     CrossRef
  • Atypical Teratoid Rhabdoid Tumor: A Possible Oriented Female Pathology?
    Cinzia Baiano, Rosa Della Monica, Raduan Ahmed Franca, Maria Laura Del Basso De Caro, Luigi Maria Cavallo, Lorenzo Chiariotti, Tamara Ius, Emmanuel Jouanneau, Teresa Somma
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Clinical predictors of survival for patients with atypical teratoid/rhabdoid tumors
    Vismaya S. Bachu, Pavan Shah, Adrian E. Jimenez, Adham M. Khalafallah, Jignesh Tailor, Debraj Mukherjee, Alan R. Cohen
    Child's Nervous System.2022; 38(7): 1297.     CrossRef
  • Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors
    Yukitomo Ishi, Yongzhan Zhang, Ali Zhang, Takahiro Sasaki, Andrea Piunti, Amreena Suri, Jun Watanabe, Kouki Abe, Xingyao He, Hiroaki Katagi, Pankaj Bhalla, Manabu Natsumeda, Lihua Zou, Ali Shilatifard, Rintaro Hashizume
    Molecular Cancer Therapeutics.2022; 21(5): 715.     CrossRef
  • Molecular targeted therapies for pediatric atypical teratoid/rhabdoid tumors
    Chang Zhang, Hao Li
    Pediatric Investigation.2022; 6(2): 111.     CrossRef
  • The results of multicenter treatment of atypical teratoid/rhabdoid tumors of the central nervous system in children under 3 years
    L. V. Olkhova, O. G. Zheludkova, L. S. Zubarovskaya, A. Yu. Smirnova, Yu. V. Dinikina, Yu. V. Kushel, A. G. Melikyan, S. K. Gorelyshev, M. V. Ryzhova, Yu. Yu. Trunin, E. I. Shults, A. G. Gevorgyan, S. V. Gorbatykh, A. N. Kislyakov, V. E. Popov, L. P. Priv
    Pediatric Hematology/Oncology and Immunopathology.2021; 20(2): 121.     CrossRef
  • 9,112 View
  • 304 Download
  • 14 Web of Science
  • 16 Crossref
Close layer
Hematologic malignancy
Differing Outcomes of Patients with High Hyperdiploidy and ETV6-RUNX1 Rearrangement in Korean Pediatric Precursor B Cell Acute Lymphoblastic Leukemia
Jae Wook Lee, Seongkoo Kim, Pil-Sang Jang, Nack-Gyun Chung, Bin Cho
Cancer Res Treat. 2021;53(2):567-575.   Published online October 8, 2020
DOI: https://doi.org/10.4143/crt.2020.507
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Recent cooperative trials in pediatric acute lymphoblastic leukemia (ALL) report long-term event-free survival (EFS) of greater than 80%. In this study, we analyzed the outcome and prognostic factors for patients with precursor B cell ALL (n=405) diagnosed during a 10-year period (2005-2015) at our institution.
Materials and Methods
All patients were treated with a uniform institutional regimen based on four risk groups, except for steroid type; patients diagnosed up till 2008 receiving dexamethasone, while subsequent patients received prednisolone. None of the patients received cranial irradiation in first complete remission.
Results
The 10-year EFS and overall survival was 76.3%±2.3% and 85.1%±1.9%. Ten-year cumulative incidence of relapse, any central nervous system (CNS) relapse and isolated CNS relapse was 20.8%±2.2%, 3.7%±1.1% and 2.5%±0.9% respectively. A comparison of established, good prognosis genetic abnormalities showed that patients with high hyperdiploidy had significantly better EFS than those with ETV6-RUNX1 rearrangement (10-year EFS of 91.2%±3.0% vs. 79.5%±4.4%, p=0.033). For the overall cohort, male sex, infant ALL, initial CNS involvement, and Philadelphia chromosome (+) ALL were significant factors for lower EFS in multivariate study, while high hyperdiploidy conferred favorable outcome. For high and very high risk patients (n=231), high hyperdiploidy was the only significant factor for EFS in multivariate study.
Conclusion
Regarding good prognosis genetic abnormalities, patients with high hyperdiploidy had significantly better outcome than ETV6-RUNX1 (+) patients. High hyperdiploidy was a major, favorable prognostic factor in the overall patient group, as well as the subgroup of patients with higher risk.

Citations

Citations to this article as recorded by  
  • Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy
    Jae-Ho Yoon, Seok Lee
    The Korean Journal of Internal Medicine.2024; 39(1): 34.     CrossRef
  • The potential role of RNA sequencing in diagnosing unexplained insensitivity to conventional chemotherapy in pediatric patients with B-cell acute lymphoblastic leukemia
    Xinyu Li, Zaoli Huang, Liwen Zhu, Weixin Lai, Yunyao Li, Han Chen, Diandian Liu, Junjiu Huang, Dunhua Zhou, Yang Li, Wenjun Weng, Honggui Xu, Luhong Xu, Zhenhua Luo, Jianpei Fang
    BMC Medical Genomics.2024;[Epub]     CrossRef
  • Distinct Immunophenotypes in the DNA Index-Based Stratification of Pediatric B-Cell Acute Lymphoblastic Leukemia
    Myriam Campos-Aguilar, Wilfrido David Tapia-Sánchez, Alberto Daniel Saucedo-Campos, Carlos Leonardo Duarte-Martínez, Sandra Olivas-Quintero, Almarosa Ruiz-Ochoa, Adolfo Rene Méndez-Cruz, Julia Reyes-Reali, María Isabel Mendoza-Ramos, Rafael Jimenez-Flores
    Cancers.2024; 16(21): 3585.     CrossRef
  • The Landscape of Secondary Genetic Rearrangements in Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia with t(12;21)
    Agnieszka Kaczmarska, Justyna Derebas, Michalina Pinkosz, Maciej Niedźwiecki, Monika Lejman
    Cells.2023; 12(3): 357.     CrossRef
  • Overview on Aneuploidy in Childhood B-Cell Acute Lymphoblastic Leukemia
    Kinga Panuciak, Emilia Nowicka, Angelika Mastalerczyk, Joanna Zawitkowska, Maciej Niedźwiecki, Monika Lejman
    International Journal of Molecular Sciences.2023; 24(10): 8764.     CrossRef
  • Construction of three‐gene‐based prognostic signature and analysis of immune cells infiltration in children and young adults with B‐acute lymphoblastic leukemia
    Chunli Xiang, Jie Wu, Liang Yu
    Molecular Genetics & Genomic Medicine.2022;[Epub]     CrossRef
  • Prognostic Value and Outcome for ETV6/RUNX1-Positive Pediatric Acute Lymphoblastic Leukemia: A Report From the South China Children’s Leukemia Group
    Kun-yin Qiu, Hong-gui Xu, Xue-qun Luo, Hui-rong Mai, Ning Liao, Li-hua Yang, Min-cui Zheng, Wu-qing Wan, Xue-dong Wu, Ri-yang Liu, Qi-wen Chen, Hui-qin Chen, Xiao-fei Sun, Hua Jiang, Xing-jiang Long, Guo-hua Chen, Xin-yu Li, Chang-gang Li, Li-bin Huang, Y
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • 7,294 View
  • 192 Download
  • 7 Crossref
Close layer
Pediatric cancer
Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis
Ying Yang, Dong Wang, Lei Cui, Hong-Hao Ma, Li Zhang, Hong-Yun Lian, Qing Zhang, Xiao-Xi Zhao, Li-Ping Zhang, Yun-Ze Zhao, Na Li, Tian-You Wang, Zhi-Gang Li, Rui Zhang
Cancer Res Treat. 2021;53(1):261-269.   Published online September 15, 2020
DOI: https://doi.org/10.4143/crt.2020.769
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We sought to investigate the effectiveness and safety of dabrafenib in children with BRAFV600E-mutated Langerhans cell histiocytosis (LCH).
Materials and Methods
A retrospective analysis was performed on 20 children with BRAFV600E-mutated LCH who were treated with dabrafenib.
Results
The median age at which the patients started taking dabrafenib was 2.3 years old (range, 0.6 to 6.5 years). The ratio of boys to girls was 2.3:1. The median follow-up time was 30.8 months (range, 18.9 to 43.6 months). There were 14 patients (70%) in the risk organ (RO)+ group and six patients (30%) in the RO group. All patients were initially treated with traditional chemotherapy and then shifted to targeted therapy due to poor control of LCH or intolerance to chemotherapy. The overall objective response rate and the overall disease control rate were 65% and 75%, respectively. During treatment, circulating levels of cell-free BRAFV600E (cfBRAFV600E) became negative in 60% of the patients within a median period of 3.0 months (range, 1.0 to 9.0 months). Grade 2 or 3 adverse effects occurred in five patients.
Conclusion
Some children with BRAFV600E-mutated LCH may benefit from monotherapy with dabrafenib, especially high-risk patients with concomitant hemophagocytic lymphohistiocytosis and intolerance to chemotherapy. The safety of dabrafenib is notable. A prospective study with a larger sample size is required to determine the optimal dosage and treatment duration.

Citations

Citations to this article as recorded by  
  • Genetic Landscape and Its Prognostic Impact in Children With Langerhans Cell Histiocytosis
    Chan-Juan Wang, Lei Cui, Shuang-Shuang Li, Hong-Hao Ma, Dong Wang, Hong-Yun Lian, Yun-Ze Zhao, Li-Ping Zhang, Wei-Jing Li, Qing Zhang, Xiao-Xi Zhao, Ying Yang, Xiao-Tong Huang, Wei Liu, Yi-Zhuo Wang, Wan-Shui Wu, Tian-You Wang, Rui Zhang, Zhi-Gang Li
    Archives of Pathology & Laboratory Medicine.2025; 149(2): 175.     CrossRef
  • Targeted therapy and immunotherapy for orbital and periorbital tumors: a major review
    Emmanuel Lee Boniao, Richard C. Allen, Gangadhara Sundar
    Orbit.2024; 43(5): 656.     CrossRef
  • Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone
    Wenqian Wang, Jian Ge, Honghao Ma, Hongyun Lian, Lei Cui, Yunze Zhao, Zhigang Li, Tianyou Wang, Rui Zhang
    BMC Pediatrics.2024;[Epub]     CrossRef
  • Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study
    Jiaying Lei, Wenxia Wang, Danna Lin, Chengguang Zhu, Wenguang Jia, Wenjun Weng, Xiaoshan Liu, Yuhan Ma, Zhixuan Wang, Lihua Yang, Xiangling He, Yunyan He, Yang LI
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Clinical features and treatment outcomes of liver involvement in paediatric Langerhans cell histiocytosis
    Xinshun Ge, Wenxin Ou, Ang Wei, Hongyun Lian, Honghao Ma, Lei Cui, Dong Wang, Liping Zhang, Xiaoman Wang, Lejian He, Rui Zhang, Tianyou Wang
    BMC Pediatrics.2024;[Epub]     CrossRef
  • Refractory juvenile xanthogranuloma of the mastoid bone responsive to trametinib
    Isaac Hauk, Ignacio Gonzalez‐Gomes, Deepak Chellapandian, Jonathan Metts, Peter H. Shaw
    Pediatric Blood & Cancer.2024;[Epub]     CrossRef
  • Advancements in the understanding and management of histiocytic neoplasms
    Kyung-Nam Koh, Su Hyun Yoon, Sung Han Kang, Hyery Kim, Ho Joon Im
    Blood Research.2024;[Epub]     CrossRef
  • Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
    Paul G. Kemps, F. J. Sherida H. Woei-A-Jin, Patrick Schöffski, Thomas Tousseyn, Isabelle Vanden Bempt, Friederike A. G. Meyer-Wentrup, Natasja Dors, Natasha K. A. van Eijkelenburg, Marijn A. Scheijde-Vermeulen, Ingrid M. Jazet, Maarten Limper, Margot Jak,
    Blood Neoplasia.2024; 1(3): 100023.     CrossRef
  • The clinical impact of serum soluble CD25 levels in children with Langerhans cell histiocytosis
    Zi-Jing Zhao, Hong-Yun Lian, Wei-Jing Li, Qing Zhang, Hong-Hao Ma, Dong Wang, Yun-Ze Zhao, Ting Zhu, Hua-Lin Li, Xiao-Tong Huang, Tian-You Wang, Rui Zhang, Lei Cui, Zhi-Gang Li
    Jornal de Pediatria.2024;[Epub]     CrossRef
  • Liver transplantation in a child with sclerosing cholangitis due to Langerhans cell histiocytosis: a case report
    Xue-Lian Wang, Chun-Xiao Fang, Min-Xia Chen, Hua-Mei Yang, Lan-Hui She, Yu Gong, Yi Xu, Wei-Qiang Xiao, Jin-Sheng Tian, Bin Ai, Li Huang, Xu-Fang Li
    Frontiers in Pediatrics.2024;[Epub]     CrossRef
  • BRAF V600E gene mutation is present in primary intraosseous Rosai-Dorfman disease
    Lokman Cevik, Swati Satturwar, Dan Jones, Joel Mayerson, Steve Oghumu, O. Hans Iwenofu
    Human Pathology.2024; 154: 105702.     CrossRef
  • Langerhans cell histiocytosis as a clonal disease of mononuclear phagocyte system
    Evgeniy F. Khynku, Maria K. Monaenkova, Olga B. Tamrazova, Alexey V. Taganov, Мarina А. Gureeva, Gayane E. Bagramova, Anton V. Molochkov
    Almanac of Clinical Medicine.2023; 50(7): 428.     CrossRef
  • Lineage switching of the cellular distribution of BRAF V600E in multisystem Langerhans cell histiocytosis
    Paul Milne, Simon Bomken, Olga Slater, Ashish Kumar, Adam Nelson, Somak Roy, Jessica Velazquez, Kshitij Mankad, James Nicholson, Dan Yeomanson, Richard Grundy, Ahmed Kamal, Anthony Penn, Jane Pears, Gerard Millen, Bruce Morland, James Hayden, Jason Lam, M
    Blood Advances.2023; 7(10): 2171.     CrossRef
  • Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors
    Ashley V. Geerlinks, Oussama Abla
    Pediatric Drugs.2023; 25(4): 399.     CrossRef
  • Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
    James A. Whitlock, Birgit Geoerger, Ira J. Dunkel, Michael Roughton, Jeea Choi, Lisa Osterloh, Mark Russo, Darren Hargrave
    Blood Advances.2023; 7(15): 3806.     CrossRef
  • Therapiestrategien bei Kindern und Jugendlichen mit Langerhanszell Histiozytosen
    Anke Elisabeth Barnbrock, Caroline Hutter, Konrad Bochennek, Milen Minkov, Thomas Lehrnbecher
    Klinische Pädiatrie.2023; 235(06): 342.     CrossRef
  • Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms
    Benjamin H. Durham, Oshrat Hershkovitz-Rokah, Omar Abdel-Wahab, Mariko Yabe, Young Rock Chung, Gilad Itchaki, Maayan Ben-Sasson, Vered A. Asher-Guz, David Groshar, Seyram A. Doe-Tetteh, Tina Alano, David B. Solit, Ofer Shpilberg, Eli L. Diamond, Roei D. M
    Blood Advances.2023; 7(23): 7319.     CrossRef
  • Validation of Liquid Chromatography Coupled with Tandem Mass Spectrometry for the Determination of 12 Tyrosine Kinase Inhibitors (TKIs) and Their Application to Therapeutic Drug Monitoring in Adult and Pediatric Populations
    Marie Bellouard, Jean Donadieu, Pauline Thiebot, Etienne Giroux Leprieur, Philippe Saiag, Isabelle Etting, Pamela Dugues, Emuri Abe, Jean-Claude Alvarez, Islam-Amine Larabi
    Pharmaceutics.2023; 16(1): 5.     CrossRef
  • Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease
    Oussama Abla
    Hematology.2023; 2023(1): 386.     CrossRef
  • Characteristics and Treatment Outcomes of Pediatric Langerhans Cell Histiocytosis with Thymic Involvement
    Ja-Feng Yao, Dong Wang, Hong-Hao Ma, Hong-Yun Lian, Li Zhang, Tian-You Wang, Zhi-Gang Li, Jin Jiang, Lei Cui, Rui Zhang
    The Journal of Pediatrics.2022; 244: 194.     CrossRef
  • Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis
    Dong Wang, Xi-Hua Chen, Ang Wei, Chun-Ju Zhou, Xue Zhang, Hong-Hao Ma, Hong-Yun Lian, Li Zhang, Qing Zhang, Xiao-Tong Huang, Chan-Juan Wang, Ying Yang, Wei Liu, Tian-You Wang, Zhi-Gang Li, Lei Cui, Rui Zhang
    Orphanet Journal of Rare Diseases.2022;[Epub]     CrossRef
  • Current perspectives on the role of liver transplantation for Langerhans cell histiocytosis: A narrative review
    Jagadeesh Menon, Ashwin Rammohan, Mukul Vij, Naresh Shanmugam, Mohamed Rela
    World Journal of Gastroenterology.2022; 28(30): 4044.     CrossRef
  • Research Progress of BRAF V600E Gene Mutation in Papillary Thyroid Carcinoma
    延泽 刘
    Advances in Clinical Medicine.2022; 12(09): 8499.     CrossRef
  • Recent advances in the understanding of the molecular pathogenesis and targeted therapy options in Langerhans cell histiocytosis
    Jin Kyung Suh, Sunghan Kang, Hyery Kim, Ho Joon Im, Kyung-Nam Koh
    BLOOD RESEARCH.2021; 56(S1): S65.     CrossRef
  • Improvement in Pituitary Imaging After Targeted Therapy in Three Children with BRAF-Mutated Langerhans Cell Histiocytosis with Pituitary Involvement


    Ying Yang, Dong Wang, Na Li, Honghao Ma, Hongyun Lian, Lei Cui, Qing Zhang, Xiaoxi Zhao, Liping Zhang, Yunze Zhao, Chanjuan Wang, Li Zhang, Tianyou Wang, Zhigang Li, Rui Zhang
    OncoTargets and Therapy.2020; Volume 13: 12357.     CrossRef
  • 34,906 View
  • 236 Download
  • 19 Web of Science
  • 25 Crossref
Close layer
Pediatric malignancy
Genome-Wide Association Study for the Identification of Novel Genetic Variants Associated with the Risk of Neuroblastoma in Korean Children
Joon Seol Bae, Ji Won Lee, Jung Eun Yoo, Je-Gun Joung, Keon Hee Yoo, Hong Hoe Koo, Yun-Mi Song, Ki Woong Sung
Cancer Res Treat. 2020;52(4):1251-1261.   Published online June 30, 2020
DOI: https://doi.org/10.4143/crt.2020.140
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Neuroblastoma (NB) is the most common extracranial solid tumor found in children. To identify significant genetic factors for the risk of NB, several genetic studies was conducted mainly for Caucasians and Europeans. However, considering racial differences, there is a possibility that genetic predispositions that contribute to the development of NB are different, and GWAS study has not yet been conducted on Korean NB patients.
Materials and Methods
To identify the genetic variations associated with the risk of pediatric NB in Korean children, we performed a genome-wide association analysis with 296 NB patients and 1000 unaffected controls (total n = 1,296) after data cleaning and filtering as well as imputation of non-genotyped SNPs using IMPUTE v2.3.2.
Results
After adjusting for multiple comparisons, we found 21 statistically significant SNPs associated with the risk of NB (Pcorr < 0.05) within 12 genes (RPTN, MRPS18B, LRRC45, KANSL1L, ARHGEF40, IL15RA, L1TD1, ANO7, LAMA5, OR7G2, SALL4, and NEUROG2). Interestingly, out of these, 12 markers were nonsynonymous SNPs. The SNP rs76015112 was most significantly associated with the risk of NB (p = 8.1E-23, Pcorr = 2.3E-17) and was located in the RPTN gene. In addition, significant nonsynonymous SNPs in ADGRE1 were found in patients with MYCN amplification (rs7256147, p = 2.6E-05). In high-risk group, rs7256147 was observed as a significant SNP (p = 5.9E-06).
Conclusion
Our findings might facilitate improved understanding of the mechanism of pediatric NB pathogenesis. However, functional evaluation and replication of these results in other populations are still needed.

Citations

Citations to this article as recorded by  
  • Expression of anoctamin 7 (ANO7) is associated with poor prognosis and mucin 2 (MUC2) in colon adenocarcinoma: a study based on TCGA data
    Chen Chen, Siripat Aluksanasuwan, Keerakarn Somsuan
    Genomics & Informatics.2023; 21(4): e46.     CrossRef
  • An Overview of Long Non-Coding (lnc)RNAs in Neuroblastoma
    Francesca Baldini, Matilde Calderoni, Laura Vergani, Paola Modesto, Tullio Florio, Aldo Pagano
    International Journal of Molecular Sciences.2021; 22(8): 4234.     CrossRef
  • 7,029 View
  • 155 Download
  • 6 Web of Science
  • 2 Crossref
Close layer
Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia
Jin Kyung Suh, Yi-Jin Gao, Jing-Yan Tang, Shiann-Tarng Jou, Dong-Tsamn Lin, Yoshiyuki Takahashi, Seiji Kojima, Ling Jin, Yonghong Zhang, Jong Jin Seo
Cancer Res Treat. 2020;52(2):359-368.   Published online July 29, 2019
DOI: https://doi.org/10.4143/crt.2019.219
AbstractAbstract PDFPubReaderePub
Purpose
The presentations and geographic incidence of pediatric non-Hodgkin lymphoma (NHL) differ from those of adults. This study delineated the characteristics and outcomes of pediatric NHL in East Asia.
Materials and Methods
Medical records of 749 pediatric patients with NHL treated at participating institutions in mainland China, Japan, Korea, and Taiwan from January 2008 to December 2013 were reviewed. Demographic and clinical features, survival outcomes, and putative prognostic factors were analyzed.
Results
Five hundred thirty patients (71%) were male. The most common pathologic subtypes were Burkitt lymphoma (BL) (36%). Six hundred seven patients (81%) had advanced diseases at diagnosis. The 5-year overall survival and event-free survival (EFS) rates were 89% and 84%. The 5-year EFS rates of BL, lymphoblastic lymphoma, and diffuse large B-cell lymphoma were 88%, 88%, and 89%, and those of anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma (PTCL) were 71% and 56% (p < 0.001). Central nervous system involvement, high lactate dehydrogenase level (> 250 IU/mL), and advanced disease at diagnosis (≥ stage III) were associated with poor outcomes (p < 0.05). ALCL and PTCL relapsed more frequently than other pathologic subtypes (p < 0.001).
Conclusion
In East Asia, PTCL was more frequent than in Western countries, and bone marrow involvement did not affect treatment outcome. This international study should motivate future collaborative study on NHL in East Asia.

Citations

Citations to this article as recorded by  
  • Hemoglobinopathies, merozoite surface protein-2 gene polymorphisms, and acquisition of Epstein Barr virus among infants in Western Kenya
    Perez K. Olewe, Shehu Shagari Awandu, Elly O. Munde, Samuel B. Anyona, Evans Raballah, Asito S. Amolo, Sidney Ogola, Erick Ndenga, Clinton O. Onyango, Rosemary Rochford, Douglas J. Perkins, Collins Ouma
    BMC Cancer.2023;[Epub]     CrossRef
  • iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin’s Lymphoma
    Runhong Yu, Linna Cheng, Shiwei Yang, Yufeng Liu, Zunmin Zhu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 8,993 View
  • 395 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05)
Sun Hyun Bae, Hee Chul Park, Won Sup Yoon, Sang Min Yoon, In-Hye Jung, Ik Jae Lee, Jun Won Kim, Jinsil Seong, Tae Hyun Kim, Taek-Keun Nam, Youngmin Choi, Sun Young Lee, Hong Seok Jang, Dong Soo Lee, Jin Hee Kim
Cancer Res Treat. 2019;51(4):1589-1599.   Published online April 10, 2019
DOI: https://doi.org/10.4143/crt.2018.687
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
There is limited data on radiotherapy (RT) for hepatocellular carcinoma (HCC) in patients with Child-Pugh classification B (CP-B). This study aimed to evaluate the treatment outcomes of fractionated conformal RT in HCC patients with CP-B.
Materials and Methods
We retrospectively reviewed the data of HCC patients with CP-B treated with RT between 2009 and 2014 at 13 institutions in Korea. HCC was diagnosed by the Korea guideline of 2009, and modern RT techniques were applied. Fraction size was ≤ 5 Gy and the biologically effective dose (BED) ≥ 40 Gy10 (α/β = 10 Gy). A total of 184 patients were included in this study.
Results
Initial CP score was seven in 62.0% of patients, eight in 31.0%, and nine in 7.0%. Portal vein tumor thrombosis was present in 66.3% of patients. The BED ranged from 40.4 to 89.6 Gy10 (median, 56.0 Gy10). After RT completion, 48.4% of patients underwent additional treatment. The median overall survival (OS) was 9.4 months. The local progression-free survival and OS rates at 1 year were 58.9% and 39.8%, respectively. In the multivariate analysis, non-classic radiation-induced liver disease (RILD) (p < 0.001) and additional treatment (p < 0.001) were the most significant prognostic factors of OS. Among 132 evaluable patients without progressive disease, 19.7% experienced non-classic RILD. Normal liver volume was the most predictive dosimetric parameter of non-classic RILD.
Conclusion
Fractionated conformal RT showed favorable OS with a moderate risk non-classic RILD. The individual radiotherapy for CP-B could be cautiously applied weighing the survival benefits and the RILD risks.

Citations

Citations to this article as recorded by  
  • Development and validation of a nomogram for radiation-induced hepatic toxicity after intensity modulated radiotherapy for hepatocellular carcinoma: a retrospective study
    Qiaoyuan Wu, Yudan Wang, Yuxin Wei, Zhengqiang Yang, Kai Chen, Jianxu Li, Liqing Li, Tingshi Su, Shixiong Liang
    Japanese Journal of Clinical Oncology.2024; 54(6): 699.     CrossRef
  • Managing hepatocellular carcinoma across the stages: efficacy and outcomes of stereotactic body radiotherapy
    Ahmed Allam Mohamed, Marie-Luise Berres, Philipp Bruners, Sven Arke Lang, Christian Trautwein, Georg Wiltberger, Alexandra Barabasch, Michael Eble
    Strahlentherapie und Onkologie.2024; 200(8): 715.     CrossRef
  • Clinical outcomes and safety of external beam radiotherapy with extensive intrahepatic targets for advanced hepatocellular carcinoma: A single institutional clinical experience
    Sunmin Park, Chai Hong Rim, Won Sup Yoon
    Saudi Journal of Gastroenterology.2024; 30(6): 399.     CrossRef
  • Role of rapid arc-image-guided radiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis: A study from tertiary care center in Punjab, India
    Manjinder Singh Sidhu, Ramandeep, Sandhya Sood, Ritu Aggarwal, Kulbir Singh, Divyanshi Sood
    Journal of Cancer Research and Therapeutics.2023; 19(3): 639.     CrossRef
  • Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child–Pugh grade B patients with locally advanced hepatocellular carcinoma
    Jian-Xu Li, Rui-Jun Zhang, Mo-Qin Qiu, Liu-Ying Yan, Mei-Ling He, Mei-Ying Long, Jian-Hong Zhong, Hai-Yan Lu, Hong-Mei Zhou, Bang-De Xiang, Shi-Xiong Liang
    Radiation Oncology.2023;[Epub]     CrossRef
  • Long-term characterization of MRI-morphologic alterations after active motion-compensated liver SBRT: a multi-institutional pooled analysis
    Constantin Dreher, Gustavo R. Sarria, Georgia Miebach, Christel Weiss, Daniel Buergy, Paulina Wojtal, Anoshirwan A. Tavakoli, David Krug, Hans Oppitz, Frank A. Giordano, Marcus Both, Frank Lohr, Jürgen Dunst, Oliver Blanck, Judit Boda-Heggemann
    Acta Oncologica.2023; 62(3): 281.     CrossRef
  • Radiotherapy trend in elderly hepatocellular carcinoma: retrospective analysis of patients diagnosed between 2005 and 2017
    Bong Kyung Bae, Jeong Il Yu, Hee Chul Park, Myung Ji Goh, Yong-Han Paik
    Radiation Oncology Journal.2023; 41(2): 98.     CrossRef
  • Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma
    Rui-Jun Zhang, Hong-Mei Zhou, Hai-Yan Lu, Hong-Ping Yu, Wei-Zhong Tang, Mo-Qin Qiu, Liu-Ying Yan, Mei-Ying Long, Ting-Shi Su, Bang-De Xiang, Mei-Ling He, Xiao-Ting Wang, Shi-Xiong Liang, Jian-Xu Li
    Radiation Oncology.2023;[Epub]     CrossRef
  • Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells
    Siqi Li, Kun Li, Kang Wang, Haoyuan Yu, Xiangyang Wang, Mengchen Shi, Zhixing Liang, Zhou Yang, Yongwei Hu, Yang Li, Wei Liu, Hua Li, Shuqun Cheng, Linsen Ye, Yang Yang
    Nature Communications.2023;[Epub]     CrossRef
  • Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: a multicenter and retrospective analysis (KROG 17-08)
    In Young Jo, Hee Chul Park, Eun Seog Kim, Seung-Gu Yeo, Myungsoo Kim, Jinsil Seong, Jun Won Kim, Tae Hyun Kim, Won Sup Yoon, Bae Kwon Jeong, Sung Hwan Kim, Jong Hoon Lee
    Japanese Journal of Clinical Oncology.2022; 52(6): 616.     CrossRef
  • Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis
    Han Ah Lee, Yeon Seok Seo, In-Soo Shin, Won Sup Yoon, Hye Yoon Lee, Chai Hong Rim
    International Journal of Surgery.2022; 104: 106753.     CrossRef
  • Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea
    Hyeong Min Park, Young-Joo Won, Mee Joo Kang, Sang-Jae Park, Sun-Whe Kim, Kyu-Won Jung, Sung-Sik Han
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile?
    Chai Hong Rim, Hye Yoon Lee, Jung Sun Kim, Hakyoung Kim
    International Journal of Radiation Biology.2021; 97(2): 111.     CrossRef
  • Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child–Pugh Class: A Nationwide Cohort Analysis in South Korea
    Sunmin Park, Chai Hong Rim, Young Kul Jung, Won Sup Yoon, Alessandro Granito
    Canadian Journal of Gastroenterology and Hepatology.2021; 2021: 1.     CrossRef
  • Benefits of Local Treatment Including External Radiotherapy for Hepatocellular Carcinoma with Portal Invasion
    Han Lee, Sunmin Park, Yeon Seo, Won Yoon, Chai Rim
    Biology.2021; 10(4): 326.     CrossRef
  • Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma
    Yeona Cho, Jun Won Kim, Ja Kyung Kim, Kwan Sik Lee, Jung Il Lee, Hyun Woong Lee, Kwang-Hun Lee, Seung-Moon Joo, Jin Hong Lim, Ik Jae Lee
    Cancers.2020; 12(6): 1612.     CrossRef
  • Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter?
    Gyu Sang Yoo, Jeong Il Yu, Hee Chul Park, Dongho Hyun, Woo Kyoung Jeong, Ho Yeong Lim, Moon Seok Choi, Sang Yun Ha
    Cancers.2020; 12(9): 2395.     CrossRef
  • Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
    Yun Hua Lee, David Tai, Connie Yip, Su Pin Choo, Valerie Chew
    Frontiers in Immunology.2020;[Epub]     CrossRef
  • 8,715 View
  • 236 Download
  • 19 Web of Science
  • 18 Crossref
Close layer
Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients
Hyery Kim, Hyoung Jin Kang, Kyung Duk Park, Kyung-Nam Koh, Ho Joon Im, Jong Jin Seo, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Hack Ki Kim, Jae Min Lee, Jeong Ok Hah, Jun Ah Lee, Young Ho Lee, Sang Kyu Park, Hee Jo Baek, Hoon Kook, Ji Yoon Kim, Heung Sik Kim, Hwang Min Kim, Hee Won Chueh, Meerim Park, Hoi Soo Yoon, Mee Jeong Lee, Hyoung Soo Choi, Hyo Seop Ahn, Yoshifumi Kawano, Ji Won Park, Seokyung Hahn, Hee Young Shin
Cancer Res Treat. 2019;51(1):357-367.   Published online May 14, 2018
DOI: https://doi.org/10.4143/crt.2017.457
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Dexrazoxane has been used as an effective cardioprotector against anthracycline cardiotoxicity. This study intended to analyze cardioprotective efficacy and secondary malignancy development, and elucidate risk factors for secondary malignancies in dexrazoxane-treated pediatric patients.
Materials and Methods
Data was collected from 15 hospitals in Korea. Patients who received any anthracyclines, and completed treatment without stem cell transplantation were included. For efficacy evaluation, the incidence of cardiac events and cardiac event-free survival rates were compared. Data about risk factors of secondary malignancies were collected.
Results
Data of total 1,453 cases were analyzed; dexrazoxane with every anthracyclines group (D group, 1,035 patients) and no dexrazoxane group (non-D group, 418 patients). Incidence of the reported cardiac events was not statistically different between two groups; however, the cardiac event-free survival rate of patients with more than 400 mg/m2 of anthracyclines was significantly higher in D group (91.2% vs. 80.1%, p=0.04). The 6-year cumulative incidence of secondary malignancy was not different between both groups after considering follow-up duration difference (non-D, 0.52%±0.37%; D, 0.60%±0.28%; p=0.55). The most influential risk factor for secondary malignancy was the duration of anthracycline administration according to multivariate analysis.
Conclusion
Dexrazoxane had an efficacy in lowering cardiac event-free survival rates in patients with higher cumulative anthracyclines. As a result of multivariate analysis for assessing risk factors of secondary malignancy, the occurrence of secondary malignancy was not related to dexrazoxane administration.

Citations

Citations to this article as recorded by  
  • Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage
    Veronika Keresteš, Jan Kubeš, Lenka Applová, Petra Kollárová, Olga Lenčová-Popelová, Iuliia Melnikova, Galina Karabanovich, Mushtaq M Khazeem, Hana Bavlovič-Piskáčková, Petra Štěrbová-Kovaříková, Caroline A Austin, Jaroslav Roh, Martin Štěrba, Tomáš Šimůn
    Toxicological Sciences.2024; 198(2): 288.     CrossRef
  • Circ-0006332 stimulates cardiomyocyte pyroptosis via the miR-143/TLR2 axis to promote doxorubicin-induced cardiac damage
    Ping Zhang, Yuanyuan Liu, Yuliang Zhan, Pengtao Zou, Xinyong Cai, Yanmei Chen, Liang Shao
    Epigenetics.2024;[Epub]     CrossRef
  • Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines
    Xiaomeng Liu, Shuping Ge, Aijun Zhang
    Children.2024; 11(7): 884.     CrossRef
  • Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines
    Parya Rahimi, Behsheed Barootkoob, Ahmed ElHashash, Arun Nair
    Cureus.2023;[Epub]     CrossRef
  • Inducing a Proinflammatory Response with Bioengineered Yeast Vacuoles with TLR2-Binding Peptides (VacT2BP) as a Drug Carrier for Daunorubicin Delivery
    Wooil Choi, Woo-Ri Shin, Yang-Hoon Kim, Jiho Min
    ACS Applied Materials & Interfaces.2023; 15(35): 41258.     CrossRef
  • Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children
    Luigia Meo, Maria Savarese, Carmen Munno, Peppino Mirabelli, Pia Ragno, Ornella Leone, Mariaevelina Alfieri
    Pharmaceutics.2023; 15(12): 2712.     CrossRef
  • Hyperhomocysteinemia as a Link of Chemotherapy-Related Endothelium Impairment
    Ashot Avagimyan
    Current Problems in Cardiology.2022; 47(10): 100932.     CrossRef
  • Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group
    Eric J. Chow, Richard Aplenc, Lynda M. Vrooman, David R. Doody, Yuan‐Shung V. Huang, Sanjeev Aggarwal, Saro H. Armenian, K. Scott Baker, Smita Bhatia, Louis S. Constine, David R. Freyer, Lisa M. Kopp, Wendy M. Leisenring, Barbara L. Asselin, Cindy L. Schw
    Cancer.2022; 128(4): 788.     CrossRef
  • Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group
    Esmée C de Baat, Elvira C van Dalen, Renée L Mulder, Melissa M Hudson, Matthew J Ehrhardt, Frederike K Engels, Elizabeth A M Feijen, Heynric B Grotenhuis, Jan M Leerink, Livia Kapusta, Gertjan J L Kaspers, Remy Merkx, Luc Mertens, Roderick Skinner, Wim J
    The Lancet Child & Adolescent Health.2022; 6(12): 885.     CrossRef
  • Cardiotoxicity After Anthracycline Chemotherapy for Childhood Cancer in a Multiethnic Asian Population
    Varen Zhi Zheng Tan, Nicole Min Chan, Wai Lin Ang, Soe Nwe Mya, Mei Yoke Chan, Ching Kit Chen
    Frontiers in Pediatrics.2021;[Epub]     CrossRef
  • Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study
    Adriana Linares Ballesteros, Roy Sanguino Lobo, Juan Camilo Villada Valencia, Oscar Arévalo Leal, Diana Constanza Plazas Hernández, Nelson Aponte Barrios, Iván Perdomo Ramírez
    Colombia Medica.2021; 52(1): e2034542.     CrossRef
  • Mechanisms and Insights for the Development of Heart Failure Associated with Cancer Therapy
    Claire Fraley, Sarah A. Milgrom, Lavanya Kondapalli, Matthew R. G. Taylor, Luisa Mestroni, Shelley D. Miyamoto
    Children.2021; 8(9): 829.     CrossRef
  • Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model
    Valentina K. Todorova, Eric R. Siegel, Yihong Kaufmann, Asangi Kumarapeli, Aaron Owen, Jeanne Y. Wei, Issam Makhoul, V. Suzanne Klimberg
    Translational Oncology.2020; 13(2): 471.     CrossRef
  • Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity
    Petra Kollárová-Brázdová, Anna Jirkovská, Galina Karabanovich, Zuzana Pokorná, Hana Bavlovič Piskáčková, Eduard Jirkovský, Jan Kubeš, Olga Lenčová-Popelová, Yvona Mazurová, Michaela Adamcová, Veronika Skalická, Petra Štěrbová-Kovaříková, Jaroslav Roh, Tom
    The Journal of Pharmacology and Experimental Therapeutics.2020; 373(3): 402.     CrossRef
  • Anthracyclines/cyclophosphamide/etoposide

    Reactions Weekly.2019; 1741(1): 28.     CrossRef
  • Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
    Sarju Ganatra, Anju Nohria, Sachin Shah, John D. Groarke, Ajay Sharma, David Venesy, Richard Patten, Krishna Gunturu, Corrine Zarwan, Tomas G. Neilan, Ana Barac, Salim S. Hayek, Sourbha Dani, Shantanu Solanki, Syed Saad Mahmood, Steven E. Lipshultz
    Cardio-Oncology.2019;[Epub]     CrossRef
  • Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
    Neha Bansal, M. Jacob Adams, Sarju Ganatra, Steven D. Colan, Sanjeev Aggarwal, Rudolf Steiner, Shahnawaz Amdani, Emma R. Lipshultz, Steven E. Lipshultz
    Cardio-Oncology.2019;[Epub]     CrossRef
  • Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – Part 2
    Antonis A. Manolis, Theodora A. Manolis, Dimitri P. Mikhailidis, Antonis S. Manolis
    Expert Opinion on Drug Safety.2018; 17(9): 893.     CrossRef
  • 10,215 View
  • 334 Download
  • 19 Web of Science
  • 18 Crossref
Close layer
Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis
Yang Li, Lin-Quan Tang, Li-Ting Liu, Shan-Shan Guo, Yu-Jing Liang, Xue-Song Sun, Qing-Nan Tang, Jin-Xin Bei, Jing Tan, Shuai Chen, Jun Ma, Chong Zhao, Qiu-Yan Chen, Hai-Qiang Mai
Cancer Res Treat. 2018;50(4):1304-1315.   Published online January 8, 2018
DOI: https://doi.org/10.4143/crt.2017.463
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to evaluate the long-term clinical outcome and toxicity of induction chemotherapy (IC) followed by concomitant chemoradiotherapy (CCRT) compared with CCRT alone for the treatment of children and adolescent locoregionally advanced nasopharyngeal carcinoma (LACANPC).
Materials and Methods
A total of 194 locoregionally advanced nasopharyngeal carcinoma patients youngerthan 21 years who received CCRT with or without IC before were included in the study population. Overall survival (OS) rate, progression-free survival (PFS) rate, locoregional recurrence-free survival (LRFS) rate, and distant metastasis-free survival (DMFS) rate were assessed by the Kaplan-Meier method and a log-rank test. Treatment toxicities were clarified and compared between two groups.
Results
One hundred and thiry of 194 patients received IC+CCRT. Patients who were younger and with more advanced TNM stage were more likely to receive IC+CCRT and intensive modulated radiotherapy. The addition of IC before CCRT failed to improve survival significantly. The matched analysis identified 43 well-balanced patients in both two groups. With a median follow-up of 51.5 months, no differences were found between the IC+CCRT group and the CCRT group in 5-year OS (83.7% vs. 74.6%, p=0.153), PFS (79.2% vs. 73.4%, p=0.355), LRFS (97.7% vs. 88.2%, p=0.083), and DMFS (81.6% vs. 81.6%, p=0.860). N3 was an independent prognostic factor predicting poorer OS, PFS, and DMFS. The addition of IC was associated with increased rates of grade 3 to 4 neutropenia.
Conclusion
This study failed to demonstrate that adding IC before CCRT could provide a significant additional survival benefit for LACANPC patients. Further investigations are warranted.

Citations

Citations to this article as recorded by  
  • Nasopharyngeal Carcinoma in Children, Current Treatment Approach
    Tal Ben-Ami
    Journal of Pediatric Hematology/Oncology.2024; 46(3): 117.     CrossRef
  • Concurrent chemoradiotherapy with or without neoadjuvant chemotherapy in pediatric patients with stage III-IVa nasopharyngeal carcinoma: a real-world propensity score-matched cohort study
    Ya-Nan Jin, Zhao-Hui Ruan, Wan-Wei Cao, Lin Yang, Wei Yao, Xiao-Feng Pei, Wang-Jian Zhang, Tia Marks, Ji-Jin Yao, Liang-Ping Xia
    Journal of Cancer Research and Clinical Oncology.2023; 149(13): 11929.     CrossRef
  • Epidemiology and treatment of head and neck malignancies in the AYA generation
    Takahiro Asakage
    International Journal of Clinical Oncology.2022; 27(3): 465.     CrossRef
  • Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020
    Yu-Jing Liang, Li-Ting Liu, Yang Li, Pan Wang, Mei-Juan Luo, Dong-Xiang Wen, Qiu-Yan Chen, Hai-Qiang Mai
    JAMA Network Open.2022; 5(3): e220173.     CrossRef
  • LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis
    Tao Xie, Kunpeng Du, Wei Liu, Chunshan Liu, Baiyao Wang, Yunhong Tian, Rong Li, Xiaoting Huang, Jie Lin, Haifeng Jian, Jian Zhang, Yawei Yuan
    British Journal of Cancer.2022; 127(7): 1239.     CrossRef
  • Exploring the Optimal Chemotherapy Strategy for Locoregionally Advanced Children and Adolescent Nasopharyngeal Carcinoma Based on Pretreatment Epstein-Barr Virus DNA Level in the Era of Intensity Modulated Radiotherapy
    Ziyi Zeng, Chen Chen, Lanlan Guo, Cheng Zhang, Lei Chen, Chuanping Yuan, Lixia Lu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study
    Ya-Nan Jin, Ji-Jin Yao, Ya-Fei You, Hui-Jiao Cao, Zi-Zi Li, Dan-Ling Dai, Wang-Jian Zhang, Tia Marks, Bei Zhang, Liang-Ping Xia
    Radiotherapy and Oncology.2021; 161: 83.     CrossRef
  • Nasopharyngeal carcinoma in children: Multimodal treatment and long‐term outcome of 92 patients in a single center over a 28‐year period
    Rejin Kebudi, Sema Bay Buyukkapu, Omer Gorgun, Kübra Ozkaya, Rasim Meral, Inci Ayan, Musa Altun
    Pediatric Blood & Cancer.2021;[Epub]     CrossRef
  • Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA
    Yu-Jing Liang, Dong-Xiang Wen, Mei-Juan Luo, Lin-Quan Tang, Shan-Shan Guo, Pan Wang, Qiu-Yan Chen, Li-Ting Liu, Hai-Qiang Mai
    European Journal of Cancer.2021; 159: 133.     CrossRef
  • Time-to-Event Supervised Genetic Algorithm Enables Induction Chemotherapy Decision Making for Nasopharyngeal Carcinoma
    Demin Liu, Haojiang Li, Liyang Wu, Shuchao Chen, Tianqiao Zhang, Wenjie Huang, Guangying Ruan, Sai Li, Lizhi Liu, Hongbo Chen
    IEEE Access.2021; 9: 98701.     CrossRef
  • LHX2 Facilitates the Progression of Nasopharyngeal Carcinoma via Activation of the FGF1/FGFR Axis
    Tao Xie, Kunpeng Du, Wei Liu, Chunshan Liu, Baiyao Wang, Yunhong Tian, Rong Li, Xiaoting Huang, Jie Lin, Haifeng Jian, Jian Zhang, Yawei Yuan
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • Prognostic impact of immunohistopathologic features in definitive radiation therapy for nasopharyngeal cancer patients
    Naoya Murakami, Taisuke Mori, Yuko Kubo, Seiichi Yoshimoto, Kimiteru Ito, Yoshitaka Honma, Takao Ueno, Kenya Kobayashi, Hiroyuki Okamoto, Narikazu Boku, Kana Takahashi, Koji Inaba, Kae Okuma, Hiroshi Igaki, Yuko Nakayama, Jun Itami
    Journal of Radiation Research.2020; 61(1): 161.     CrossRef
  • The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis
    Bi-Cheng Wang, Bo-Ya Xiao, Guo-He Lin, Chang Wang, Quentin Liu
    BMC Cancer.2020;[Epub]     CrossRef
  • Update in pediatric nasopharyngeal undifferentiated carcinoma
    Line Claude, Emmanuel Jouglar, Loig Duverge, Daniel Orbach
    The British Journal of Radiology.2019;[Epub]     CrossRef
  • 8,621 View
  • 211 Download
  • 18 Web of Science
  • 14 Crossref
Close layer
Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study
Loredana Amoroso, Giovanni Erminio, Guy Makin, Andrew D. J. Pearson, Penelope Brock, Dominique Valteau-Couanet, Victoria Castel, Marlène Pasquet, Genevieve Laureys, Caroline Thomas, Roberto Luksch, Ruth Ladenstein, Riccardo Haupt, Alberto Garaventa, SIOPEN Group
Cancer Res Treat. 2018;50(1):148-155.   Published online March 21, 2017
DOI: https://doi.org/10.4143/crt.2016.511
AbstractAbstract PDFPubReaderePub
Purpose
Metastatic response to induction therapy for high-risk neuroblastoma is a prognostic factor. In the International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) HR-NBL-1 protocol, only patients with metastatic complete response (CR) or partial response (PR) with ≤ three abnormal skeletal areas on iodine 123-metaiodobenzylguanidine ([123I]mIBG) scintigraphy and no bone marrow disease proceed to high dose therapy (HDT). In this study, topotecan-vincristine-doxorubicin (TVD) was evaluated in patients failing to achieve these criteria, with the aim of improving the metastatic response rate.
Materials and Methods
Patients with metastatic high-risk neuroblastoma who had not achieved the SIOPEN criteria for HDT after induction received two courses of topotecan 1.5 mg/m2/day for 5 days, followed by a 48-hour infusion of vincristine, 2 mg/m2, and doxorubicin, 45 mg/m2.
Results
Sixty-three patients were eligible and evaluable. Following two courses of TVD, four (6.4%) patients had an overall CR, while 28 (44.4%) had a PR with a combined response rate of 50.8% (95% confidence interval [CI], 37.9 to 63.6). Of these, 23 patients achieved a metastatic CR or a PR with ≤ 3 mIBG skeletal areas and no bone marrow disease (36.5%; 95% CI, 24.7 to 49.6) and were eligible to receive HDT. Toxicity was mostly haematological, affecting 106 of the 126 courses (84.1%; 95% CI, 76.5 to 90.0), and dose reduction was necessary in six patients. Stomatitis was the second most common nonhematological toxicity, occurring in 20 patients (31.7%).
Conclusion
TVD was effective in improving the response rate of high-risk neuroblastoma patients after induction with COJEC enabling them to proceed to HDT. However, the long-term benefits of TVD needs to be determined in randomized clinical trials.

Citations

Citations to this article as recorded by  
  • ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition
    Marcus Borenäs, Ganesh Umapathy, Dan E. Lind, Wei-Yun Lai, Jikui Guan, Joel Johansson, Eva Jennische, Alexander Schmidt, Yeshwant Kurhe, Jonatan L. Gabre, Agata Aniszewska, Anneli Strömberg, Mats Bemark, Michael N. Hall, Jimmy Van den Eynden, Bengt Hallbe
    Proceedings of the National Academy of Sciences.2024;[Epub]     CrossRef
  • Development of red blood cell-derived extracellular particles as a biocompatible nanocarrier of microRNA-204 (REP-204) to harness anti-neuroblastoma effect
    Wararat Chiangjong, Jirawan Panachan, Sujitra Keadsanti, David S. Newburg, Ardythe L. Morrow, Suradej Hongeng, Somchai Chutipongtanate
    Nanomedicine: Nanotechnology, Biology and Medicine.2024; 60: 102760.     CrossRef
  • Elevated Expression of LGR5 and WNT Signaling Factors in Neuroblastoma Cells With Acquired Drug Resistance
    John Clark-Corrigall, Svetlana Myssina, Martin Michaelis, Jindrich Cinatl, Shafiq Ahmed, Jane Carr-Wilkinson
    Cancer Investigation.2023; 41(2): 173.     CrossRef
  • Computational intelligence analysis of high-risk neuroblastoma patient health records reveals time to maximum response as one of the most relevant factors for outcome prediction
    Davide Chicco, Riccardo Haupt, Alberto Garaventa, Paolo Uva, Roberto Luksch, Davide Cangelosi
    European Journal of Cancer.2023; 193: 113291.     CrossRef
  • Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
    Aleksandra Wieczorek, Anna Zaniewska-Tekieli, Karoline Ehlert, Katarzyna Pawinska-Wasikowska, Walentyna Balwierz, Holger Lode
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Adaptation of the Th-MYCN Mouse Model of Neuroblastoma for Evaluation of Disseminated Disease
    Seyed M. Rahavi, Maryam Aletaha, Ali Farrokhi, Amanda Lorentzian, Philipp F. Lange, Christopher A. Maxwell, Chinten James Lim, Gregor S. D. Reid
    International Journal of Molecular Sciences.2023; 24(15): 12071.     CrossRef
  • Challenging diagnosis of Mycolicibacterium cosmeticum/canariasense infection: A case report and literature review
    Daniel Grupel, Orly Sagi, Israel Nissan, Rona Grossman, Motro Yair, Jacob Moran-Gilad, Dana Danino
    Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.2023; 33: 100393.     CrossRef
  • Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
    Aleksandra Wieczorek, Urszula Żebrowska, Marek Ussowicz, Agnieszka Sokół, Marzena Stypińska, Bożenna Dembowska-Bagińska, Katarzyna Pawińska-Wąsikowska, Walentyna Balwierz
    Journal of Clinical Medicine.2023; 12(16): 5252.     CrossRef
  • Characterization and therapeutic perspectives of differentiation-inducing therapy in malignant tumors
    Kangwei Zhu, Yuren Xia, Xindi Tian, Yuchao He, Jun Zhou, Ruyu Han, Hua Guo, Tianqiang Song, Lu Chen, Xiangdong Tian
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
    Juan Muñoz, Cristina Larrosa, Saray Chamorro, Sara Perez-Jaume, Margarida Simao, Nazaret Sanchez-Sierra, Amalia Varo, Maite Gorostegui, Alicia Castañeda, Moira Garraus, Sandra Lopez-Miralles, Jaume Mora
    Cancers.2023; 15(19): 4837.     CrossRef
  • Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation
    Diana Treis, Ganesh Umapathy, Susanne Fransson, Jikui Guan, Patricia Mendoza-García, Joachim T. Siaw, Sandra Wessman, Lena Gordon Murkes, Jakob J. E. Stenman, Anna Djos, Lotta H. M. Elfman, John Inge Johnsen, Bengt Hallberg, Ruth H. Palmer, Tommy Martinss
    JCO Precision Oncology.2022;[Epub]     CrossRef
  • High-Risk Neuroblastoma: Poor Outcomes Despite Aggressive Multimodal Therapy
    Adil Abdelhamed Abbas, Alaa Mohammed Noor Samkari
    Current Cancer Therapy Reviews.2022; 18(1): 14.     CrossRef
  • Multi-omics integration reveals a six-malignant cell maker gene signature for predicting prognosis in high-risk neuroblastoma
    Zijun Yan, Qiming Liu, Ziyang Cao, Jinxia Wang, Hongyang Zhang, Jiangbin Liu, Lin Zou
    Frontiers in Neuroinformatics.2022;[Epub]     CrossRef
  • Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
    Nur Olgun, Emre Cecen, Dilek Ince, Deniz Kizmazoglu, Birsen Baysal, Ayse Onal, Ozhan Ozdogan, Handan Guleryuz, Riza Cetingoz, Ayse Demiral, Mustafa Olguner, Ahmet Celik, Serra Kamer, Erdener Ozer, Zekiye Altun, Safiye Aktas
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience
    P. Berlanga, C. Pasqualini, U. Pötschger, C. Sangüesa, M.R. Castellani, A. Cañete, R. Luksch, M. Elliot, G. Schreier, M. Kropf, D. Morgenstern, V. Papadakis, S. Ash, E. Ruud, P. Brock, A. Wieczorek, P. Kogner, T. Trahair, P. Ambros, T. Boterberg, V. Caste
    European Journal of Cancer.2021; 144: 1.     CrossRef
  • Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta
    Richa Jain, Amita Trehan, Prema Menon, Rakesh Kapoor, Nandita Kakkar, Srinivasan Radhika, Akshay Kumar Saxena, Bhagwant Rai Mittal, Neelam Varma, Ram Samujh, Deepak Bansal
    Pediatric Hematology and Oncology.2021; 38(4): 291.     CrossRef
  • Neuroblastoma
    Christine Chung, Tom Boterberg, John Lucas, Joseph Panoff, Dominique Valteau‐Couanet, Barbara Hero, Rochelle Bagatell, Christine E. Hill‐Kayser
    Pediatric Blood & Cancer.2021;[Epub]     CrossRef
  • Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by MYCN gene gain/amplification and remission status: a nationwide registration study in Japan
    Yuya Saito, Mitsuyoshi Urashima, Yoshiyuki Takahashi, Atsushi Ogawa, Chikako Kiyotani, Yuki Yuza, Katsuyoshi Koh, Kenichiro Watanabe, Yoshiyuki Kosaka, Hiroaki Goto, Atsushi Kikuta, Keiko Okada, Yuhki Koga, Junya Fujimura, Masami Inoue, Atsushi Sato, Yosh
    Bone Marrow Transplantation.2021; 56(9): 2173.     CrossRef
  • Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma
    Paolo Uva, Maria Carla Bosco, Alessandra Eva, Massimo Conte, Alberto Garaventa, Loredana Amoroso, Davide Cangelosi
    Cancers.2021; 13(11): 2809.     CrossRef
  • Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients
    T. Bauters, D. Heenen, K. Norga, A. Van Damme, A. Uyttebroeck, G. Laureys
    European Journal of Pediatrics.2021; 180(9): 3067.     CrossRef
  • Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
    Neofit Spasov, Mariya Spasova, Stella Stabouli
    Case Reports in Pediatrics.2021; 2021: 1.     CrossRef
  • Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study
    Alberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Martin Elliott, Shifra Ash, Godfrey C. F. Chan, Geneviève Laureys, Maja Beck-Popovic, Kim Vettenranta, Walentyna Balwierz, Henrik Schroeder, Cormac Owens, Ma
    Journal of Clinical Oncology.2021; 39(23): 2552.     CrossRef
  • Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics
    Jan Škubník, Vladimíra Svobodová Pavlíčková, Tomáš Ruml, Silvie Rimpelová
    Biology.2021; 10(9): 849.     CrossRef
  • Extending the Applicability of In Ovo and Ex Ovo Chicken Chorioallantoic Membrane Assays to Study Cytostatic Activity in Neuroblastoma Cells
    Miguel Angel Merlos Rodrigo, Berta Casar, Hana Michalkova, Ana Maria Jimenez Jimenez, Zbynek Heger, Vojtech Adam
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
    Joanna Szydzik, Dan E. Lind, Badrul Arefin, Yeshwant Kurhe, Ganesh Umapathy, Joachim Tetteh Siaw, Arne Claeys, Jonatan L. Gabre, Jimmy Van den Eynden, Bengt Hallberg, Ruth H. Palmer
    Nature Communications.2021;[Epub]     CrossRef
  • Association of PARP1 polymorphisms with response to chemotherapy in patients with high‐risk neuroblastoma
    Marianna Avitabile, Vito Alessandro Lasorsa, Sueva Cantalupo, Antonella Cardinale, Flora Cimmino, Annalaura Montella, Dalila Capasso, Riccardo Haupt, Loredana Amoroso, Alberto Garaventa, Alessandro Quattrone, Maria Valeria Corrias, Achille Iolascon, Mario
    Journal of Cellular and Molecular Medicine.2020; 24(7): 4072.     CrossRef
  • Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
    Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Shifra Ash, Genevieve Laureys, Penelope Brock, Jean Marie Michon, Cormac Owens, Toby Trahair, Godfrey Chi Fung Chan, Ellen Ruud, Henrik Schroeder, Maja Beck-Pop
    Cancers.2020; 12(2): 309.     CrossRef
  • Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR
    F. Berthold, A. Faldum, A. Ernst, J. Boos, D. Dilloo, A. Eggert, M. Fischer, M. Frühwald, G. Henze, T. Klingebiel, C. Kratz, B. Kremens, B. Krug, I. Leuschner, M. Schmidt, R. Schmidt, R. Schumacher-Kuckelkorn, D. von Schweinitz, F.H. Schilling, J. Theisse
    Annals of Oncology.2020; 31(3): 422.     CrossRef
  • Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma
    S. L. George, V. Parmar, F. Lorenzi, L. V. Marshall, Y. Jamin, E. Poon, P. Angelini, L. Chesler
    Journal of Experimental & Clinical Cancer Research.2020;[Epub]     CrossRef
  • Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study
    Keith Holmes, Ulrike Pötschger, Andrew D. J. Pearson, Sabine Sarnacki, Giovanni Cecchetto, Javier Gomez-Chacon, Roly Squire, Enrique Freud, Adam Bysiek, Lucas E. Matthyssens, Martin Metzelder, Tom Monclair, Jakob Stenman, Michal Rygl, Lars Rasmussen, Jean
    Journal of Clinical Oncology.2020; 38(25): 2902.     CrossRef
  • Development of differentiation modulators and targeted agents for treating neuroblastoma
    Zegao Jin, Yang Lu, Yizhe Wu, Jinxin Che, Xiaowu Dong
    European Journal of Medicinal Chemistry.2020; 207: 112818.     CrossRef
  • A promoter-driven assay for INSM1-associated signaling pathway in neuroblastoma
    Chiachen Chen, Michael S. Lan
    Cellular Signalling.2020; 76: 109785.     CrossRef
  • Evolving treatments in high-risk neuroblastoma
    Abhinav Kumar, John P J Rocke, B Nirmal Kumar
    Expert Opinion on Orphan Drugs.2020; 8(12): 497.     CrossRef
  • Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects
    Yao Wang, Jeffrey H. Stear, Ashleigh Swain, Xing Xu, Nicole S. Bryce, Michael Carnell, Irina B. Alieva, Vera B. Dugina, Timothy P. Cripe, Justine Stehn, Edna C. Hardeman, Peter W. Gunning
    Molecular Cancer Research.2020; 18(7): 1074.     CrossRef
  • Cardiac MRI: a Promising Diagnostic Tool to Detect Cancer Therapeutics–Related Cardiac Dysfunction
    Jasmin D. Haslbauer, Sarah Lindner, Gesine Bug, Eike Nagel, Valentina O. Puntmann
    Current Cardiovascular Imaging Reports.2019;[Epub]     CrossRef
  • Therapy intensification in high-risk neuroblastoma patients with poor response to standard induction: experience of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
    T. V. Shamanskaya, D. Y. Kachanov, A. V. Dumacheva, M. V. Teleshova, D. V. Shevtcov, T. V. Sergeeva, A. M. Syleimanova, R. A. Moiseenko, Y. N. Likar, . Kailash, S. R. Varfolomeeva
    Pediatric Hematology/Oncology and Immunopathology.2019; 18(4): 19.     CrossRef
  • Molecular mechanisms and therapeutic targets in neuroblastoma
    John Inge Johnsen, Cecilia Dyberg, Susanne Fransson, Malin Wickström
    Pharmacological Research.2018; 131: 164.     CrossRef
  • Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma
    Fabio Morandi, Loredana Amoroso, Alessandra Dondero, Roberta Castriconi, Stefano Parodi, Roberto Luksch, Fiorina Casale, Aurora Castellano, Alberto Garaventa, Alessandro Moretta, Cristina Bottino, Mirco Ponzoni, Maria Valeria Corrias
    OncoImmunology.2018; 7(9): e1468953.     CrossRef
  • Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma
    Joshua Felgenhauer, Laura Tomino, Julia Selich-Anderson, Emily Bopp, Nilay Shah
    Neoplasia.2018; 20(10): 965.     CrossRef
  • Prise en charge des neuroblastomes de haut risque : l’expérience du groupe européen SIOPEN
    Dominique Valteau-Couanet, Gudrun Schleiermacher, Sabine Sarnacki, Claudia Pasqualini
    Bulletin du Cancer.2018; 105(10): 918.     CrossRef
  • Novel Therapies for Relapsed and Refractory Neuroblastoma
    Peter E. Zage
    Children.2018; 5(11): 148.     CrossRef
  • Investigational drugs in phase II clinical trials for the treatment of neuroblastoma
    Loredana Amoroso, Riccardo Haupt, Alberto Garaventa, Mirco Ponzoni
    Expert Opinion on Investigational Drugs.2017; 26(11): 1281.     CrossRef
  • 11,833 View
  • 578 Download
  • 40 Web of Science
  • 42 Crossref
Close layer
Gonadal and Sexual Dysfunction in Childhood Cancer Survivors
Ju Young Yoon, Hyeon Jin Park, Hee Young Ju, Jong Hyung Yoon, Jin Soo Chung, Sang Hyun Hwang, Dong Ock Lee, Hye Young Shim, Byung-Kiu Park
Cancer Res Treat. 2017;49(4):1057-1064.   Published online January 25, 2017
DOI: https://doi.org/10.4143/crt.2016.197
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Few studies have addressed gonadal and sexual dysfunctions in childhood cancer survivors. We evaluated the prevalence rates and risk factors for gonadal failure among adolescent/young adult childhood cancer survivors and their sexual function.
Materials and Methods
Subjects were childhood cancer survivors aged 15-29 years who had completed therapy more than 2 years ago. Demographic and medical characteristics were obtained from the patients’ medical records. In addition, hormonal evaluation and semen analysis were performed and sexual function was evaluated via questionnaire.
Results
The study included 105 survivors (57 males, 48 females), of which 61 were adults (age > 19 years) and 44 were adolescents. In both males and females, the proportion of survivors with low sex hormone levels did not differ among age groups or follow-up period. Thirteen female subjects (27.1%) needed sex hormone replacement, while five males subjects (8.8%) were suspected of having hypogonadism, but none were receiving sex hormone replacement. Of 27 semen samples, 14 showed azospermia or oligospermia. The proportion of normospermia was lower in the high cyclophosphamide equivalent dose (CED) group (CED ≥ 8,000 mg/m2) than the low CED group (27.3% vs. 62.5%, p=0.047). Among adults, none were married and only 10 men (35.7%) and eight women (34.3%) were in a romantic relationship. Though a significant proportion (12.0% of males and 5.3% of females) of adolescent survivors had experienced sexual activity, 13.6% had not experienced sex education.
Conclusion
The childhood cancer survivors in this study showed a high prevalence of gonadal/sexual dysfunction; accordingly, proper strategies are needed to manage these complications.

Citations

Citations to this article as recorded by  
  • Sexual and reproductive complications and concerns of survivors of childhood, adolescent and adult cancer
    Brigitte Gerstl, Christina Signorelli, Claire E. Wakefield, Rebecca Deans, Tejnei Vaishnav, Karen Johnston, Kristen Neville, Richard J. Cohn, Antoinette Anazodo
    Journal of Cancer Survivorship.2024; 18(4): 1201.     CrossRef
  • α‐Ketoglutarate Improves Ovarian Reserve Function in Primary Ovarian Insufficiency by Inhibiting NLRP3‐Mediated Pyroptosis of Granulosa Cells
    Ke Liu, Yafei Wu, Wenqin Yang, Tianlong Li, Zhongxu Wang, Shu Xiao, Zhenghua Peng, Meng Li, Wenhao Xiong, Meixiang Li, Xi Chen, Shun Zhang, Xiaocan Lei
    Molecular Nutrition & Food Research.2024;[Epub]     CrossRef
  • Huangqi‐Guizhi‐Wuwutang protects against oligospermia in mice by promoting the proliferation of spermatogenic stem cells: A comprehensive study using HPLC‐Q‐TOF/MS and experimental pharmacology
    Yuan Zhao, Jinru Wu, Xiangbin Li, Lin Zheng, Qiugu Chen, Shangbin Zhang, Jianping Chen
    Biomedical Chromatography.2024;[Epub]     CrossRef
  • Sexual Dysfunction Among Adolescent and Young Adult Men Diagnosed with Cancer
    Quinn Carroll Rainer, Justin Michael Dubin, Navin Chakravarthy Balaji, Victoria Troesch, William Terry, Varun Monga, Lindsey Clifford, Jamie Shoag, Aubrey Greer, Sirpi Nackeeran, Alejandro Aaron Rodriguez, Premal Patel, Lisa Paz, Bruce Richard Kava, Warre
    Journal of Adolescent and Young Adult Oncology.2023; 12(1): 93.     CrossRef
  • Reproductive Care of Childhood and Adolescent Cancer Survivors: A 12-Year Evaluation
    Antoinette Catherine Anazodo, Sumin Choi, Christina Signorelli, Sarah Ellis, Karen Johnston, Claire E. Wakefield, Rebecca Deans, Kristen A. Neville, Richard J. Cohn
    Journal of Adolescent and Young Adult Oncology.2021; 10(2): 131.     CrossRef
  • Fatherhood Following Treatment for Testicular Cancer: A Systematic Review and Meta-Analyses
    Brigitte Gerstl, Michael J. Bertoldo, Elizabeth Sullivan, Xanthie Volckmar, Aidan Kerr, Handan Wand, Angela Ives, Olayan Albalawi, Antoinette Anazodo
    Journal of Adolescent and Young Adult Oncology.2020; 9(3): 341.     CrossRef
  • Male and Female Sexual Dysfunction in Pediatric Cancer Survivors
    Daniel R. Greenberg, Yash S. Khandwala, Hriday P. Bhambhvani, Pamela J. Simon, Michael L. Eisenberg
    The Journal of Sexual Medicine.2020; 17(9): 1715.     CrossRef
  • Novel therapies for childhood cancer and impact on puberty
    Christina Wei, Michael Stevens, Elizabeth Crowne
    Current Opinion in Endocrine and Metabolic Research.2020; 14: 112.     CrossRef
  • Psychosexual Functioning of Female Childhood Cancer Survivors: A Report From the St. Jude Lifetime Cohort Study
    Kari L. Bjornard, Carrie R. Howell, James L. Klosky, Wassim Chemaitilly, Deo Kumar Srivastava, Tara M. Brinkman, Daniel M. Green, Victoria W. Willard, Lisa M. Jacola, Matthew J. Krasin, Melissa M. Hudson, Leslie L. Robison, Kirsten K. Ness
    The Journal of Sexual Medicine.2020; 17(10): 1981.     CrossRef
  • Male sexual dysfunction: A review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention
    Lei Chen, Guang-rui Shi, Dan-dan Huang, Yang Li, Chen-chao Ma, Min Shi, Bin-xiao Su, Guang-jiang Shi
    Biomedicine & Pharmacotherapy.2019; 112: 108585.     CrossRef
  • Survival from cancer in young people: An overview of late effects focusing on reproductive health
    Hannah L. Newton, Amanda J. Friend, Richard Feltbower, Catherine J. Hayden, Helen M. Picton, Adam W. Glaser
    Acta Obstetricia et Gynecologica Scandinavica.2019; 98(5): 573.     CrossRef
  • Clinical ascertainment of health outcomes in Asian survivors of childhood cancer: a systematic review
    Long Hin Jonathan Poon, Chun-Pong Yu, Liwen Peng, Celeste Lom-Ying Ewig, Hui Zhang, Chi-Kong Li, Yin Ting Cheung
    Journal of Cancer Survivorship.2019; 13(3): 374.     CrossRef
  • The impact of childhood cancer and its treatment on puberty and subsequent hypothalamic pituitary and gonadal function, in both boys and girls
    Christina Wei, Elizabeth Crowne
    Best Practice & Research Clinical Endocrinology & Metabolism.2019; 33(3): 101291.     CrossRef
  • Urological Survivorship Issues Among Adolescent Boys and Young Men Who Are Cancer Survivors
    Troy Sukhu, Sherry Ross, R. Matthew Coward
    Sexual Medicine Reviews.2018; 6(3): 396.     CrossRef
  • 11,478 View
  • 300 Download
  • 17 Web of Science
  • 14 Crossref
Close layer
Case Report
Two Pediatric Osteosarcoma Cases with Delayed Methotrexate Excretion: Its Clinical Course and Management
Kang Min Lee, Hee Woo Lee, Seung Yeon Kim, Hyeon Jeong Lee, Dong Hwan Kim, Joongbum Cho, Dong Ho Kim, Jung Sub Lim, Jin Kyung Lee, Jun Ah Lee
Cancer Res Treat. 2011;43(1):67-70.   Published online March 31, 2011
DOI: https://doi.org/10.4143/crt.2011.43.1.67
AbstractAbstract PDFPubReaderePub
High-dose methotrexate (MTX) chemotherapy extends the duration of hospitalization and introduces the risks of serious complications related to delayed MTX excretion. The treatment of delayed MTX excretion is largely dependent on invasive measures such as hemodialysis because the clinical data regarding the efficacy or safety of carboxypetidase G2 is limited. We report here on the cases of two pediatric osteosarcoma patients with delayed MTX excretion and who were successfully managed using supportive measures. Potential life-threatening complications were prevented by administering high doses of leucovorin.

Citations

Citations to this article as recorded by  
  • The Role of Single Nucleotide Polymorphisms in Transporter Proteins and the Folate Metabolism Pathway in Delayed Methotrexate Excretion: A Case Report and Literature Review
    Jun Wang, Yue-Tao Zhao, Meng-Jiao Sun, Feng Chen, Hong-Li Guo
    Pharmacogenomics and Personalized Medicine.2022; Volume 15: 919.     CrossRef
  • Toxicité rénale des anticancéreux
    Blandine Aloy, Nicolas Janus, Corine Isnard-Bagnis, Gilbert Deray, Vincent Launay-Vacher
    Néphrologie & Thérapeutique.2021; 17(7): 553.     CrossRef
  • Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients
    Wei Zhang, Qing Zhang, Ting-Ting Zheng, Jian-Cun Zhen, Xiao-Hui Niu
    Chinese Medical Journal.2016; 129(21): 2530.     CrossRef
  • 8,924 View
  • 53 Download
  • 3 Crossref
Close layer
Original Articles
Initial Response to Treatment was Highly Associated with the Prognosis of Childhood Rhabdomyosarcoma: A Retrospective Analysis of a Single Center Experience in Korea
Jeong A Park, Eun Kyung Kim, Hyoung Jin Kang, Hee Young Shin, Il Han Kim, Hyo Seop Ahn
Cancer Res Treat. 2008;40(3):111-115.   Published online September 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.3.111
AbstractAbstract PDFPubReaderePub
Purpose

Following the introduction of a multimodal approach to diagnosis and treatment, the prognosis of rhabdomyosarcoma (RMS) has markedly improved over the last three decades. However, there are few data on treatment outcomes in Korean patients.

Materials and Methods

We performed a retrospective analysis of 77 patients with RMS diagnosed and treated at Seoul National University Children's Hospital between 1986 and 2005.

Results

The overall 5-year survival and event-free survival rates for all patients were 77% and 59%, respectively. The Intergroup Rhabdomyosarcoma Study clinical grouping and initial response to treatment (20-week response) were important prognostic factors.

Conclusions

The outcome of childhood RMS was closely associated with the initial staging and the initial response to treatment. Modulating therapies according to initial responses and risk factors is critical, and new treatment strategies for high-risk patients are needed.

Citations

Citations to this article as recorded by  
  • Adherence to Treatment, Response and Patterns of Failure in Pediatric Parameningeal Rhabdomyosarcoma: Experience From a Tertiary Cancer Care Center From India
    Soumyajit Roy, Sushmita Pathy, Bidhu K. Mohanti, Subhash Chander, Ahitagni Biswas
    Journal of Pediatric Hematology/Oncology.2017; 39(2): e62.     CrossRef
  • Pediatric rhabdomyosarcoma in India: A single-center experience
    Deepak Bansal, Anirban Das, Amita Trehan, Rakesh Kapoor, Naresh K. Panda, Radhika Srinivasan, Nandita Kakkar, Kushaljit S. Sodhi, Akshay K. Saxena, Katragadda Lakshmi Narasimha Rao
    Indian Pediatrics.2017; 54(9): 735.     CrossRef
  • The impact of radiotherapy on clinical outcomes in parameningeal rhabdomyosarcoma
    Yunseon Choi, Do Hoon Lim
    Radiation Oncology Journal.2016; 34(4): 290.     CrossRef
  • Rhabdomyosarcoma Treatment and Outcome at a Multidisciplinary Pediatric Cancer Center in Lebanon
    Maysaa Salman, Hani Tamim, Fouad Medlej, Tarek El-Ariss, Fatima Saad, Fouad Boulos, Toufic Eid, Samar Muwakkit, Nabil Khoury, Miguel Abboud, Raya Saab
    Pediatric Hematology and Oncology.2012; 29(4): 322.     CrossRef
  • Solid tumours of childhood
    Bruce O. Okoye
    Surgery (Oxford).2010; 28(8): 382.     CrossRef
  • Primary meningeal rhabdomyosarcoma associated with chronic subdural effusion
    Ji Yeoun Lee, Bo Sung Kim, Ji Hoon Phi, Hyoung Jin Kang, Sung-Hye Park, Kyu-Chang Wang, Il Han Kim, Byung-Kyu Cho, Seung-Ki Kim
    Journal of Neurosurgery: Pediatrics.2010; 5(2): 167.     CrossRef
  • 10,243 View
  • 38 Download
  • 6 Crossref
Close layer
A Study of the Survival Rate of Childhood Cancer in Korea
Mi Hwa Yang, Song Hyeun Eun, Chan Sook Park, Jin A Son, Jae Yun Kim, Jae Wook Ko, Don Hee Ahn
Cancer Res Treat. 2001;33(3):191-198.   Published online June 30, 2001
DOI: https://doi.org/10.4143/crt.2001.33.3.191
AbstractAbstract PDF
PURPOSE
It is known that the prognosis of childhood cancer is relatively good, however actual representative nationwide data on childhood cancer, particularly of survival rate, are rare. In this study we attempted to establish the overall survival rate of major childhood cancer.
MATERIALS AND METHODS
The primary source of data of childhood cancer under 15 years of age were the registry files of the Central Cancer Registry Report (Ministry of Health & Welfare) from 1993 to 1997. The above data was compared to death case data files of the same period obtained from the Korea National Statistical Office using the personal identification code. We calculated the 1, 3, and 5 year survival rates using the life table of SPSS and Kaplan-Meier method and compared the survival rate of disease according to prognostic factors.
RESULTS
A total of 6,720 cases of pediatric cancer from the Central Cancer Registry files were computerized and sorted by personal identification (ID) code to extract duplicated cases as well as cases with incomplete data. The final number of cases entered in this study was 4,983. 1) The number of confirmed death cases was 1,448 (29.1%). 2) The disease distribution showed that the most common pediatric cancer was leukemia (1,468/4,983, 29%), followed by brain tumors (503/4,983, 10%), lymphoma (315/4,983, 6%), Wilms tumor (165/4,983, 3%), etc. in order by number of patients. 3) The 5 year survival rate of disease was as follows: overall 62%, acute lymphocytic leukemia 61%, acute non-lymphocytic leukemia 32%, malignant lymphoma 72%, neuroblastoma 47%, medulloblastoma 51%, Astrocytoma 66%, Wilms tumor 83%, etc.
CONCLUSION
We analyzed and report the 5 year survival rate of overall childhood cancer and of each of the twelve major childhood cancers from in Korea 1993 to 1997 to provide basic data on childhood cancer statistics.

Citations

Citations to this article as recorded by  
  • Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study
    Kyung-Nam Koh, Ho Joon Im, Hyery Kim, Hyoung Jin Kang, Kyung Duk Park, Hee Young Shin, Hyo Seop Ahn, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Young Tak Lim, Jun Eun Park, Byung-Kiu Park, Hyeon Jin Park, Jong Jin Seo
    Journal of Korean Medical Science.2017; 32(4): 642.     CrossRef
  • Inequalities in childhood cancer mortality according to parental socioeconomic position: A birth cohort study in South Korea
    Mia Son, Jongoh Kim, Juhwan Oh, Ichiro Kawachi
    Social Science & Medicine.2011; 72(1): 108.     CrossRef
  • Korean Pediatric/Adolescent Lymphoma - Incidence and Pathologic Characteristics -
    Seung-Sook Lee, Jin-Man Kim, Young-Hyeh Ko, Jooryung Huh, Chang Suk Kang, Chul Woo Kim, Yun Kyung Kang, Jai Hyang Go, Min Kyung Kim, Wan-Seop Kim, Yoon Jung Kim, Hyun-Jung Kim, Hee Kyung Kim, Jong Hee Nam, Hyung Bae Moon, Chan-Kum Park, Tae In Park, Young
    The Korean Journal of Pathology.2010; 44(2): 117.     CrossRef
  • Clinical Results of Chemotherapy based Treatment in Retinoblastoma Patients: A Single Center Experience
    Hyery Kim, Ji Won Lee, Hyoung Jin Kang, Hyeon Jin Park, Yoon Yi Kim, Hee Young Shin, Young Suk Yu, Il Han Kim, Hyo Seop Ahn
    Cancer Research and Treatment.2008; 40(4): 164.     CrossRef
  • Clinicopathologic Features and Treatment Outcomes in Malignant Lymphoma of Pediatric and Young Adult Patients in Korea: Comparison of Korean All-Ages Group and Western Younger Age Group
    In Gyu Hwang, Keon Hee Yoo, Soo Hyun Lee, Yeon Hee Park, Tae Kyu Lim, Sang Cheol Lee, Sara Park, Byeong-Bae Park, Young Hyeh Ko, Kihyun Kim, Hong Hoe Koo, Won Seog Kim
    Clinical Lymphoma and Myeloma.2007; 7(9): 580.     CrossRef
  • 4,485 View
  • 44 Download
  • 5 Crossref
Close layer
Case report
Secretory Carcinoma of the Breast in Three Year-old Girl: A Case report
Woo Chul Noh, Nam Sun Paik, Kyung Ja Cho, Jin Haeng Chung, Seung Kon Nam, Doo Hwan Choe, Nan Mo Moon
J Korean Cancer Assoc. 2000;32(4):822-826.
AbstractAbstract PDF
Secretory carcinoma is one of the least common forms of breast cancer and demonstrates distinctive clinical and pathological characteristics. We herein report a case of secretory carcinoma of the breast in 3 year and 1 month-old girl. At presentation, the patient had a 2.5cm sized mass on her left breast which was firmly attached to the overlying nipple. The aspiration cytologic findings of the tumor were consistent with a secretory carcinoma. After confirming malignancy by frozen section diagnosis, a modified radical mastectomy was performed and secretory carcinoma was finally diagnosed. To our knowledge, secretory breast carcinoma in children has not been reported previously in Korea and this seems to be the youngest case of secretory carcinoma of the breast which had been reported in English literature.
  • 2,978 View
  • 42 Download
Close layer
Original Articles
A Clinical Study of Pediatric Myelodysplastic Syndrome: Application of International Prognostic Scoring System and the Review of the Korean Literature
Hoon Kook, Chan Jong Kim, Weon Sang Yoon, Na Eun Ryu, Kyoung Joong Chung, Tai Ju Hwang
J Korean Cancer Assoc. 2000;32(1):178-190.
AbstractAbstract PDF
PURPOSE
Myelodysplastic syndrome (MDS) in children needs to be elucidated in terms of clinical characteristics, natural history, the most effective treatment and prognostic factors, as the disease is very rare and its definition and classification has not reached a consensus by many physician. This study was aimed to describe the characteristics and the disease courses of Korean children with MDS, and to analyze the usefulness of prognostic scoring systems in the prediction of transformation to acute myelogenous leukemia (AML) and overall survival among subgroups.
MATERIALS AND METHODS
Fourteen children with MDS seen at Chonnam University Hospital and additional 59 patients identified by the review of Korean literature were evaluated to define clinical characteristics and disease courses. Kaplan-Meier (K-M) probability of leukemic transformation and overall survival were plotted. FAB subtypes, subgroups by Boumemouth Scoring System (BSS), and International Prognostic Scoring System (IPSS) risk groups were compared to predict transformation to AML and overall survival.
RESULTS
The median age of 14 patients was 36.5 months. The sex ratio was 3.7:1 (M: F). The frequency of FAB subtypes in Korea was similar to that of other countries except for higher proportion of RA (37%). K-M 3-yr probability of AML transformation and survival for Korean patients were 54.7%, and 49.8%, respectively. Although FAB system, BMS and IPSS were all capable of discriminating subgroups in the prediction of AML transformation and survival, they did not reach the significant level possibly due to small number of patients assigned to each subgroup.
CONCLUSION
The clinical characteristics of Korean children with MDS were not different from those of other countries. This study showed the high rate of AML transformation and poor survival in children with MDS.
  • 2,858 View
  • 31 Download
Close layer
Pediatric Pancreatic Tumors
Dae Yeon Kim, Min Gew Choi, Ki Hong Kim, In One Kim, Sung Eun Jung, Seong Cheol Lee, Kwi Won Park, Woo Ki Kim
J Korean Cancer Assoc. 1999;31(4):830-835.
AbstractAbstract PDF
PURPOSE
Pancreatic tumors are relatively rare in children. Until now more than 150 cases have been reported in the English literature. In this paper, the authors report the tumors clinical characteristics and the results of surgery in eleven children.
MATERIALS AND METHODS
Eleven cases of pancreatic tumor pathologically verified at Seoul National University Children's Hospital between 1984 to 1998 were retrospectively analyzed. Four were boys and seven were girls, and their mean age at diagnosis was 7.7 (range, 2 13) years.
RESULTS
There were six solid and papillary epithelial neoplasms of the pancreas (SPENP) and five pancreatoblastomas. All children came to medical attention because of abdominal masses. Tumors ranged in size from 6.0X 5.0 cm to 10.5 x 8.0 cm. Eight tumors were located in head and three in tail. Complete excision was performed in eight cases (six in SPENP and two in pancreatoblastoma). Incomplete excision was performed in two cases of pancreatoblastoma. One patient with pancreatoblastoma had an unresectable tumor at the time of diagnosis and needle aspiration biopsy was done under the ultrasound guidance. No patient died during surgery. After a mean follow-up period of 4.1 years, all patients with SPENP were alive and there had been no recurrence. However, of two patients who received complete excision in pancreatoblastoma, one presented with liver metastasis at 4 months after operation and received chemotherapy, but died 6 months after operation. The other patient had local recurrence 1 year after operation. Reoperation and chemotherapy were performed and the child is now alive without evidence of disease montbs after the initial operation. All three patients with unresectable tumor died in spite of adjuvant radiotherapy and chemotherapy.
CONCLUSION
Pediatric pancreatic tumors comprise rare heterogenous groups of malignancies with their prognosis dependent upon adequate resection and pathologic classification. Complete resection of pancreatic tumors arising anywhere in the pancreas was recommended.
  • 2,715 View
  • 17 Download
Close layer
Geographical Variations in the Incidence of Childhood Cancer
Duk Hee Lee, Hai Rim Shin, Kang Weon Park, Yoon Ok Ahn
J Korean Cancer Assoc. 1998;30(3):425-434.
AbstractAbstract PDF
PURPOSE
The incidence of childhood cancer in the Korea was studied to compare incidence rates between countries and between different regions in Korea.
MATERIALS AND METHODS
A tatal of 2,891 cases, registered in the Natinal Cancer Registy from 1993 to 1995, were analysied. Death Certificate Only(DCO) cases were not included. DCO % was estimated about 22%. We calculated the incidence rates according to the International Classification of Childhood Cancer. The age-standardized rates by diagnostic group was compared with those of other countries. The total incidence of childhood cancer were compared among 34 cities in Korea with the rates in the rest of the nation.
RESULTS
The crude incidence of all childhood cancer was 94.1 per million. The cumulative incidence to age 15 was 0.137% and the age-standardized rate, calculated using the world standard population, was 96.1 per million. In the incidence rates by diagnostic group, we observed many similarities with other countries in East Asia. The age-standardized rates of E, F and AL cities were significantly higher(p<0.05). In the 0-4 age group, F, AL and BB cities showed higher rates(p<0.05). In 5~9 years and 10~14 years, F city only had higher rates(p<0.05).
CONCLUSION
Further study will be needed in order to investigate possible environmental factors which may account for the regional variations.
  • 2,582 View
  • 15 Download
Close layer
A Study on the Significance of Peripheral T-lymphocyte Subsets and Mitogen-induced Lymphocyte Prolicaraction in Acute Lymphoblastic Leukemia in Childhood
Sang Hyun Byun, Jong Jin Seo, Young Hun Chung
J Korean Cancer Assoc. 1990;22(2):257-267.
AbstractAbstract PDF
To evaluate the relationship between peripheral blood T-lymphocyte subsets, mitogen-induced lymphocyte proliferation and the outcome of acute lymphoblastic leukemia in childhood, the authors studied 15 cases of acute Iymphoblastic leukemia in childhood. The results were as follows: 1 I Percent peripheral lymphocyte and percent CDS+ cells showed no significant difference between total patient group and control group, while percent CD4+ cells was significantly decreased in total patient group compared to control group. But no significant difference was found between patient subgroups 2) Total counts of CD4+ cells and CD8+cells showed no significant difference between patient subgroups. 3) The ratio of CD4+cells and CDB+ cells showed no significant difference between patient subgroups, but more cases with the ratio less than 1.0 were found among total patient group compared to control group. 4) The stimulation indices of PHA and Con-A were significantly decreased in total patient group (p<0.05, p<0.005) compared to control group, but no significant difference was observed between patient subgroups. 5) The unstimulated 3[H]-thymidine uptake showed no significant relationship between patient subgroups. 6) The distribution of T-lymphocyte subsets showed no significant relationship with the stimula- tion index of PHA and Con-A. These results showed that the children with acute lymphoblastic leukemia have depressed cellular immune functions tested with T-lymphocvte subsets and mitagen-induced lymphocyte proliferation assay. But these results can not be regarded as one of prognostic factors of acute lymphoblastic leukemia in childhood unless there are additional longterm data indicating the T-cell mediated immune functions are related to the outcome of acute lymphoblastic leukemia in childhood.
  • 2,356 View
  • 13 Download
Close layer
Effect of Filgrastim ( rhG - CSF ) on Chemotherapy Induced Neutropenia in Pediatric Acute Myelogenous Leukemia Patients
Hee Young Shin, Hee Young Shin, Seong Hoon Hah, Hong Hoe Koo, Hyo Seop Ahn
J Korean Cancer Assoc. 1994;26(1):136-144.
AbstractAbstract PDF
To determine the safety and efficacy of rhG-CSF on chemotherapy induced neutropenia in pediatric AML patients, we conducted a prospective controlled study in 17 patiens with AML at Seoul National University Childrens Hospital from July, 1993 to January, 1994. High dose cytosine arabinoside(Ara-C, 3gm/m for four times every 12 hours) with L-asparaginase 6,000 u/m) were given to 13 patients as Group I control and after the recovery of WBC, same chemo- therapy followed by G-CSF(50 ug/m for 10 days) were given as Group I study. In Group II study, high dose Ara-C(3gm/m(2) for 8 times every 12 hours) were given to 11 patients with AML followed by G-CSF(150 ug/m for 10 days). Recovery of the absolute neutrophil counts to more than 1,000/mm' was significantly faster in the G-CSF group than in the control group(P< 0.01) and the absolute neutrophil counts on day 14 of chemotherapy was significantly higher in G-CSF group(P<0.01). The toxicity of G-CSF was minimal and there was no evidence of accel- erated growth of leukemic blasts during the G-CSF treatment. In conclusion, Filgrastim(rhG- CSF) promotes the recovery of neutrophils and shortens the duration of neutropenia induced by the chemotherapy in pediatric acute myelogenous leukemia.
  • 2,644 View
  • 19 Download
Close layer
Effect of rhGM-CSF on the Chemotherapy - induced Neutropenia of Children with Solid Tumors
Jong Jin Seo, Sang Won Cha, Sang Mee Lee, Kyu Don Kim
J Korean Cancer Assoc. 1995;27(2):322-331.
AbstractAbstract PDF
To investigate the clinical effectiveness of recombinant human GM-CSF(rhGM-CSF; Leucogen) on the chemotherapy-induced neutropenia, twelve children with malignant solid tumor who had neutropenia after chemotherapy received 250 pg/M(2)/day of rhGM-CSF subcutaneouly for 10 consecutive days from the fifth day of next chemotherapy were schedule using the same rekimen. rhGM-CSF significantly increased leukocyte, neutrophil and eosinophil counts on the tenth day of GM-CSF course compared to the control course(P<0.05), but there was no significant difference in the counts of monocyte, lymphocyte, platelet or hemoglobin(p>0.1). The nadir of leukocyte and neutrophil were significantly higher in GM-CSF course than those of control course (P<0.05), but there was no significant difference in that of monocyte, lymphocyte, eo- sinophil, platelet or hemoglobin(P: 0.1). The duration of chemotherapy-induced leukopenia and neutropenia were decreased significantly in GM-CSF course than those of control course(P< 0.05). The duration of antibiotics administration and febrile period during chemotherapy were shorter in GM-CSF course without statistical significance. No significant side effect was observed during rhGM-CSF course. These results indicate that rhGM-CSF(Leucogen') is effective in alleviating the chemotherapy-induced neutropenia of children with malignant solid tumors.
  • 2,706 View
  • 21 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP